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PREFACE 
Serum cholesterol is one of the analytes that is frequently measured 
in the clinical laboratory. This is because of the established relationship 
between elevated serum cholesterol level and the risk of coronary heart 
disease (CHO). Lately, the distribution of cholesterol among the major 
solubilizing lipoproteins, namely, very low density lipoproteins (VLDL), 
low density lipoprotein (LDL), and high density lipoprotein (HDL) has also 
become important in determining CHD risks. Studies have shown that the 
risk of developing CHD is positively correlated with total cholesterol and 
LDL and negatively correlated with HDL. These findings led to an 
increased effort to measure not only total cholesterol but also its 
distribution among the lipoprotein fractions for early detection and 
management of CHD. Current routine methods for measuring the 
lipoprotein fractions involve three enzymatic tests and are not applicable to 
samples with triglyceride levels > 400 mg/dL. This study offers an 
alternative routine method for obtaining the lipid profile in a single non-
enzymatic test. The applicability of the alternative method to samples that 
have high triglyceride levels as well as samples with lipid disorders was 
evaluated. 
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CHAPTER I 
INTRODUCTION 
Diseases of the heart and blood vessels are still the leading cause of 
death in the United States and other industrialized societies. The largest 
groups of these deaths are associated with myocardial infarction (Ml) and 
coronary heart disease (CHD).1 Coronary heart disease is a common, life-
threatening and disabling disease which can be difficult to treat and very 
expensive to cure. In the United States alone, about one million Americans 
suffer MI each year, and more than six million have symptoms of CHD. 
Illness due to CHD costs over $50 billion annually for care, loss of 
earnings, and productivity. 2 
Coronary heart disease and myocardial infarction are a consequence 
of atherosclerosis, a disease of the arteries. Accumulation of lipids in the 
cytoplasm of arterial cells is an early manifestation of atherosclerosis at the 
cellular level. Initial deposition of intracellular lipids transported into the 
vessel wall by lipoprotein plays an important role in the initiation of 
atherosclerotic lesions. 3•4 Once a lesion has started, lipids, particularly 
cholesterol, accumulate within the extracellular space of the intima of 
human arteries. This process thickens the arterial wall and reduces the 
1 
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lumen of the artery, resulting in reduced blood flow. Reduced blood flow 
will decrease the supply of oxygen to the tissues and can cause injury or 
even death to tissues. When this happens in the coronary arteries, the result 
is a MI or heart attack. 
Results from many studies have shown that there are a large number 
of factors involved in the development of atherosclerosis. The following 
factors seem to be the most important: hyperlipidemia, genetic factors, 
hypertension, cigarette smoking, type A personality, elevated blood 
glucose, obesity, race, age, gender, and lack of exercise.5 Recently, the 
effects of serum levels of lipoprotein(a)6•7 and fibrinogen8 have been added 
to the list. The precise way in which these risk factors promote 
atherosclerosis is not clear. 
Among the lipids, cholesterol is the most atherogenic. A large body 
of evidence9-12 has shown that an elevated blood cholesterol level is one of 
the principal risk factors for CHD. In 1985, the United States' National 
Institute of Health inaugurated the National Cholesterol Education Program 
(NCEP) with the goal of planning strategies to reduce the prevalence of 
elevated blood cholesterol in the United States and thereby reduce the 
incidence of CHD. The NCEP strongly encourages the public to have their 
serum cholesterol levels examined and be aware of the implications of 
elevated cholesterol. This recommendation created the need for automated 
methods for serum cholesterol determinations that can provide results 
quickly in order to be able to handle the huge numbers of samples that 
would be analyzed in the various screening programs. Cholesterol 
screening outside the confines of the conventional laboratory are not at all 
unusual today. Physicians' offices, pharmacies, shopping malls, worksites, 
supermarkets, and high traffic public areas are all common venues. Even 
home testing of cholesterol levels is now possible. The methods used for 
cholesterol determination differ in complexity from simple non-
instrumental card tests to sophisticated multi-analyte analyzers. 
Cholesterol and other lipids play an important role in human 
metabolism, participating in such diverse functions as the maintenance of 
cellular integrity, the storage of energy, the provision of metabolic 
3 
intermediates and the transmission and transduction of signals. 13 In order 
to be solubilized in the aqueous environment of the blood and be 
transported through the body, lipids are associated with amphipathic 
proteins. The complex micellar structures of lipids and proteins are called 
lipoproteins. Protein moieties of the lipoprotein are known as apo-
lipoproteins or apoproteins and serve as co-factors in enzyme and receptor 
site reactions for synthesis and degradation of lipoprotein complexes. 
Three major classes of lipoproteins in the normal fasting state of 
human serum are usually recognized. These are very low density lipo-
proteins (VLDL), low density lipoproteins (LDL) and high density lipo-
proteins (HDL). Each of these lipoproteins is heterogeneous in terms of 
size, lipid composition, and apoprotein composition. Very low density 
lipoprotein and LDL components transport lipids from the liver to the 
various cells in the body. Very low density lipoprotein transports mainly 
triglyceride, while LDL is the main carrier of cholesterol in human blood 
plasma. Low density lipoprotein taken up by cells lining the arteries are 
responsible for atherosclerosis. High density lipoprotein fractions on the 
other hand, facilitate removal of excess cholesterol and other lipids from 
the blood and body cells by returning them to the liver for degradation to 
bile acids and ultimate excretion. 
In the last two decades, more and more attention has been focused on 
the role of the different lipoprotein classes and their relative effects on 
CHD risks. Studies have shown that the risk of developing CHD is 
positively correlated with total cholesterol (TC) and low density lipo-
protein cholesterol (LDL-C), and negatively correlated with high density 
4 
lipoprotein cholesterol (HDL-C).14-18 There has been no direct evidence to 
implicate the very low density lipoprotein cholesterol (VLDL-C) in CHD 
risk determinations, but a high triglyceride (TG) level can be a serious 
problem by itself. However, HDL-C and TG are said to exhibit a strong 
inverse association.19 The NCEP concluded that lipoproteins, particularly 
LDL-C and HDL-C offer more precise information than TC as risk factors 
for predicting the chances of CHD. 
The need for better criteria to characterize CHD risks in patients has 
led to a rapid increase in the demand for the measurement of lipoprotein 
classes by clinical laboratories. Assay of TC is now largely relegated to the 
status of a screening test. Although many methods are currently available 
for lipoprotein determination, the current routine method used to obtain a 
lipid profile is based on three independent measurements. Total cholesterol, 
HDL-C, and TG are measured directly by enzymatic methods. To deter-
mine HDL-C, VLDL-C and LDL-C are selectively precipitated with one of 
the commonly used reagents, such as manganese heparin, dextran sulfate, 
or magnesium phosphotungstate.20 The HDL-C remaining in solution is 
measured by the same enzymatic method used for TC. Based on consider-
able evidence, the VLDL-C fraction is taken to be equal to one-fifth of the 
TG value as long as TG is not >400 mg/dL. Low density lipoprotein 
cholesterol is estimated using the Friedewald formula, 21 
LDL-C = TC - ( HDL-C + TG/5 ) . (eq. 1) 
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The LDL-C fraction is the one known with least accuracy because of the 
propagation of errors in the measurement of TC, HDL-C, and TG, and the 
empirical nature of the equation. 
The Laboratory Standardization Panel (LSP). of the NCEP has 
emphasized the need to improve upon the precision and accuracy of the 
measurements of lipoproteins among different clinical laboratories, and has 
recommended that clinical laboratories should ultimately obtain a precision 
consistent with coefficients of variation (CV) of S 3% for TC and LDL-C 
and S 4% for HDL-c.22-23 In terms of accuracy, LSP recommends a bias 
of S + 3 % of the result of the reference method. Despite great 
improvements in accuracy and precision in the measurement of TC and the 
lipoprotein classes, there is still a need for reliable methods for the 
measurement of serum LDL-C24 and HDL-C25 that are suitable for 
routine use in the clinical laboratory. 
The goal of this research project was to develop an alternative 
method to determine the three major lipid fractions directly in a single 
experiment. Previous attempts26•27 have been reported to measure these 
three lipid fractions simultaneously. Results from these studies yielded only 
a very good correlation between methods for LDL-C. The intent of this 
study was to improve the correlation for all three major lipid fractions and 
to surpass the LSP requirements for analytical accuracy and precision. The 
current routine method has a limitation in estimating LDL-C for hyper-
triglyceridemic serum (TG >400 mg/dL). As a further aspiration, the 
applicability of the alternative method to measuring cholesterol in hyper-
triglyceridemic samples was evaluated. 
CHAPTER II 
THE CHEMISTRY OF CHOLESTEROL AND ITS RELATION TO 
CORONARY HEART DISEASE 
I. Early Chemistry of Cholesterol 
Cholesterol was first described towards the end of the eighteenth 
century by the French chemist de Fourcroy who isolated a crystalline 
substance from the alcohol-soluble fraction of human gallstones.28 This 
substance was also mentioned by Poulletier de la Salle more than twenty 
years earlier. De Fourcroy considered that his substance was related to 
cetyl palmitate; but early in the next century, Chevreul showed this not to 
be so. Chevreul also gave de Fourcroy's substance the name cholesterine. 
Lecanu detected the presence of cholesterol in the blood of humans while 
Chevreul and Couerbe had found it in human and animal bile as well as in 
the brain. It was soon detected as a normal constituent of all animal cells, as 
well as in several secretions and pathological deposits. For instance, Vogel 
found it in atheromatous arteries and Muller found it in a type of tumors 
which he called cholesteatomes. 29 
In 1859, Berthelot showed that cholesterol was an alcohol and 
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prepared esters of it. Other cholesterol esters like the oleate and palmitate 
were isolated from serum by Hurthle while the palmitate and stearate were 
found in normal adrenals by Rosenheim and Tebb in 1909 .29 
Wislecenus and Moldenhauer prepared a dibromide of cholesterol, 
indicating the existence of a double bond. In 1898, Reinetzer published the 
correct empirical formula and Windaus in 1919 proposed a tentative 
structural formula for cholesterol. Advances in x-ray crystallography and 
synthetic chemistry enabled both Windaus and Wieland and Dane to deduce 
the correct structural .formula for cholesterol in 1932.29•30 
II. Physical and Chemical Properties of Cholesterol 
Cholesterol is the principal sterol of mammalian tissue. In humans, 
it occurs in particularly high concentrations in the brain, spinal cord and 
adrenal glands. About 17% of the solid matter of the brain is free 
cholesterol. 28 
The basic structure of cholesterol is a tetracyclic perhydrocyclo-
pentanophenanthrene skeleton that is typical for steroid molecules. Its 
molecular weight is 387 g/mole~ Fig.la shows the flat structural form and 
Fig.lb the conformational representation of the cholesterol molecule. 
Substituents are a double bond at carbon atom 5 (C-5), a saturated 
branched side chain of eight carbon atoms at C-17, and two ~-oriented 
methyl groups at C-10 and C-13. The hydroxyl group at C-3 and the 
hydrogen atom at C-8 are also~- oriented. Hydrogen atoms at C-3, C-9, 
C-14, and C-17 are all situated below the plane of the molecule ( cx-
oriented). The A to B, B to C, and C to D ring junctions are all in trans-
configurations. Substituents at C-20 are in the R-configuration.31 
The 3-J3-hydroxyl group is the only polar group in the cholesterol 
molecule. It is only very slightly soluble in water (solubility is about 0.2 
mg I 100 mL water) and quite soluble in organic solvents. It has a melting 
point of 149.5-150°C.32 
H 
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Fig. la. Flat structural representation of cholesterol. 
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Fig.lb. Conformational representation of cholesterol. 
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The presence of several asymmetric carbon atoms render solutions 
of cholesterol optically active and this property is an aid in identifying and 
9 
in ascertaining the analytical purity of cholesterol preparations. The optical 
activity of cholesterol is [a] 20= -31.5° in ether and [a] 20= -39.5° in 
D D 
chloroform. 32 When crystallized from anhydrous organic solvents, 
cholesterol forms triclinic needles, and when crystallized from 95% 
alcoholic solution, it separates as monohydrate, rhomb-shaped triclinic 
plates, which lose water at 70-80°C. The absorption maximum of 
cholesterol in ethanol occurs at 206 nm (EM = 3400 ).33 
1.0 
The chemistry of cholesterol is not particularly complex. Most of the 
reactions occur at the hydroxyl group, at the double bond or at carbon 7.29 
A variable fraction of cholesterol is present in the human body as 
cholesterol esters formed by condensation of the alcohol group with long 
chain fatty acids that generally contain 16-20 carbon atoms.33 
The glycoside digitonin, the saponins tigonin and gitonin, and the 
alkaloid tomatine interact with tl;ie 3(3-hydroxyl group of cholesterol 
causing it to be precipitated. The reaction is specific for sterols containing 
the 3(3-hydroxyl group, which provides a basis for procedures designed to 
measure free cholesterol in biological materials.33 
The double bond between C-5 and C-6 can be hydrogenated and 
halogenated. The formation of halide, especially dibromide, has been of 
great practical use in purifying cholesterol obtained from natural sources. 
Interactions between cholesterol and sulfuric acid yield intensely colored 
compounds and this has been the basis of a number of colorimetric 
determinations. 33 
Cholesterol complexes readily with the salts CaC!i• 2H20 and 
MgCh• 6H20. Complexes contain two cholesterol molecules and one 
molecule of the salt. It is probable that these salts occur at sites of 
cholesterol deposition. 31 
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Cholesterol readily undergoes auto-oxidation even when stored in 
crystalline form. The main auto-oxidation products are 7 -ketocholesterol, 
7a- and 7~- hydroxycholesterols, cholestane-3~, Sa-, 6~-triol, and 25-
hydroxycholesterol. 31 
III. Origin and Function of Cholesterol in the Body 
Cholesterol present in human and animal tissues has a dual origin. 
Part originates in the diet and the remainder is synthesized in the body 
from acetyl CoA, the active form of acetic acid. The quantitative 
contributions of these two sources are highly variable. 33 The daily dietary 
intake of cholesterol ranges from Oto 1.2 g,34-35 while the total quantity 
synthesized in the human body averages 1.0 g/day, about 80% of which is 
produced by the liver.36-38 Numerous studies 36•39-43 have shown that 
dietary cholesterol, absorbed from the gastrointestinal tract, can inhibit 
cholesterol synthesis in the liver, which appears to be the principal 
mechanism by which the level of cholesterol in the body is controlled. 
Cholesterol is the major sterol in man and a component of virtually 
all cell surfaces and intra-cellular membranes. It is also a substrate for the 
formation of other essential substances that include: (1) the bile acids, 
which are synthesized in the liver and function to facilitate the absorption 
of dietary triglycerides and fat, (2) various steroid hormones (e.g. proge-
sterone, corticosteroids, estrogens), which have widely different physio-
11 
logical properties, and (3) vitamin D3, the only vitamin normally 
synthesized in sufficient quantities by the body and therefore not required 
in the diet. 44 
IV. Transport of Cholesterol and Other Lipids in the Body: The 
Lipoproteins 
To solubilize the hydrophobic cholesterol and other lipids in the 
aqueous environment of the blood and to transport them throughout the 
body, lipids are associated with proteins. The lipids and proteins are not 
covalently attached but are associated by hydrophobic interaction.45 The 
macromolecular lipid-protein complexes are referred to as lipoproteins and 
have characteristic sizes, densities and compositions. Protein moieties of the 
lipoproteins are known as apoproteins or apolipoproteins. They are 
responsible for the metabolism of the lipoproteins by interacting with the 
different enzymes and receptors in the body. Besides lipid transport, 
lipoproteins also regulate lipid synthesis and metabolism.46 
Plasma lipoproteins are globular, essentially spherical micelle-like 
particles, that consist of a nonpolar core of triglycerides and cholesteryl 
esters sorrounded by an amphipathic coating of protein, phospholipid, and 
free cholesterol.45 The several classes of lipoproteins are based upon their 
differences in sizes, floating densities in an ultracentrifugal field, or 
electrophoretic mobilities. Each lipoprotein class has a characteristic 
composition, but the amounts of lipid and protein do not occur in fixed 
proportions within each class.4749 Lipoproteins are, therefore, viewed as 
a continuous spectrum of molecular aggregates with a changing pattern of 
components.48•50 The different human serum lipoproteins and their 
properties and composition are summarized in Table 1. 
A. Chylomicrons 
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The term chylomicron was first used by Gage52 in 1920 to describe 
the luminous lipid particles observed under the dark field microscope in 
blood samples after ingestion of fat. Chylomicrons are the largest and 
lightest of the lipoproteins, with diameters ranging from 700-12000A and a 
density less than 0.95 g/mL.so-st,53-54 They are composed mainly of lipids 
(97.5-99.2%) with average percent by weight compositions that are 80-
95% triglyceride, 1-3% free cholesterol, 2-4% esterified cholesterol, 3-6% 
phospholipids, and 1-2% protein. 53 On electrophoresis of lipoproteins on 
paper, agarose gel or polyacrylamide gel, chylomicrons remain at the 
origin. The major protein components are apo-C and apo-B.so-st,53-54 
Resemblances have been noted between the composition of the protein 
moiety of the chylomicrons and that of HDL. As such it has been suggested 
that the HDL are utilized by the intestinal cells for the synthesis of chylo-
microns. 55 
Chylomicrons are the principal form of lipoproteins in which the 
absorbed triglycerides are transported from the intestines to the various 
organs in the body.56 They are synthesized in the small intestine in 
response to the absorption of dietary fat. Most, but not all, of the lipid is of 
dietary origin. The absorbed lipid is re-esterified within the intestinal 
epithelial cell and then undergoes further synthetic steps involving 
phospholipids and apoproteins before secretion from the cell as a chy lo-
Table 1. Classification, Properties, and Composition of Human Serum Lipoproteins.51 
Measurement Chylomicron VLDL IDL IDL HDL 
Hydrated density, 0.93 0.97 1.003 1.034 1.121 
Solvent density for 
<1.006 <1.006 1.006-1.019 1.019-1.063 1.063-1.21 isolation, g/m1 
Molecular weiJdtt (0.4-30) X 109 (5-10) X 1()6 (3.9-4.8) X 1()6 2.75 X 1()6 (1.75-3;6) X 105 
Diameter, nm >70 25.0-70.0 22.0-24.0 19.6-22.7 4-10 
Electrophoretic mobility Origin Pre-~ 
(paper, agarose) 
Broad ~ (between ~ a ~ and pre-~) 
Composition, % by 
weight 
Cholesterol, unesteri:fied 2 5-8 8 13 6 
Cholesterol, esteri:fied 5 11-14 22 49 13 
Phospholipid 7 20-23 25 27 28 
Triglyceride 84 44-60 30 11 3 
Protein 2 4-11 15 23 50 
Synthesis Intestine Liver,intestine Intravascular Intravascular Intestine, liver 
Apoproteins, %total 
AI 7.4 Trace - - 67 
All 4.2 Trace - - 22 
B-100 Trace 36.9 50-70 98 Trace 
B-48 22.5 Trace Trace - -
CI CII. CIII 66 49.9 5-10 Trace 5-11 
Ell. Elli EIV - 13.0 10-20 Trace 1-2 
D 
- - - -
Trace 
-
L,.l 
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micron. 
Following release from the intestinal mucosa! cells into the lymph, 
nascent chylomicrons enter the systemic circulation via the thoracic duct, 
and are rapidly metabolized with a plasma half life of 5 to 15 minutes. 
Transfer of apo A-I and apo A-II to HDL and reciprocal transfers of C and 
E apoproteins from HDL serve to enhance the hydrolysis of chylomicron-
triglycerides by the enzyme lipoprotein lipase (LPL), and provide a source 
of chylomicron surface components that act as precursors of nascent HDL 
particles. This process occurs predominantly in the capillary beds of 
muscle and adipose tissue, and results in the progressive delipidation of the 
chylomicron particle. Progressive hydrolysis of chylomicron's tri-
glycerides leads to the formation of a smaller chylomicron, the chylo-
micron remnant. 57 
Plasma drawn from normal human subjects more than 12 hours after 
ingestion of fat contains few if any chylomicrons.58 In certain disorders 
however, the concentration and persistence of chylomicrons may be greatly 
increased. In a hereditary disease known as F~drickson type I hyperlipo-
proteinemia59 ( or hyperchylomicronemia), there is a defect in the activity 
of the enzyme LPL, which is responsible for the removal from plasma of 
the triglyceride of both chylomicrons and VLDL. Lack of LPL activity 
may be due either to its absence or to the lack of the activator enzyme, the 
protein Apo C-Il.51 In another disorder known as endogenous 
(carbohydrate induced) lipemia, chylomicrons compete with the increased 
VLDL for LPL induced triglyceride hydrolysis. 
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B. Very low density lipoprotein {VLDL or pre-i}) 
The VLDL class of lipoproteins covers a wide spectrum of particles, 
having a diameters from 280-750A, hydrated densities of 0.95-1.006g/mL 
and flotation values from 20-400.47 From their relative mobility on 
electrophoresis they are sometimes referred to as pre-~ lipoproteins.53 
Particle sizes are directly proportional to the TO content and inversely 
proportional to the phospholipid and protein content.47 Average percent by 
weight compositions of VLDL are 55% triglyceride, 20% phospholipid, 
15% cholesterol (30% of which is esterified), and 10% protein.56 The 
major apoprotein of VLDL is apo B-100 with lesser amounts of apo-C 
polypeptides and apo-E.57 
Very low density lipoprotein particles serve to transport endogenous 
triglycerides from the liver to the peripheral tissues. The liver is the major 
site of synthesis of VLDL, for which apo B-100 is a constitutive apoprotein 
but the small intestine will also produce significant amounts of VLDL. 60 
Many factors including nutrient intake, plasma concentration of free fatty 
acids, and levels of insulin and epinephrine in plasma, appear to modulate 
the hepatic secretion of VLDL, which in tum influences VLDL 
concentrations in plasma. 57 
Particles of VLDL are metabolized more slowly than chylomicrons. 
Under normal conditions, the half life of VLDL apo-B is 6 to 12 hours. 
The metabolisms of VLDL and chylomicrons show many similarities, but 
one important difference is that the remnant particles, which result from 
VLDL lipolysis, can be either taken up by the liver via apo E mediated 
catabolism or subsequently converted to LDL. Metabolism of VLDL to 
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LDL is the major source of the latter lipoprotein in human plasma. 57 
There are many diseases and metabolic disorders in which moderate 
to massive increases in VLDL are observed. One such disorder is 
Fredrickson type N hyperlipoproteinemia,59•61 an inherited recessive 
disease. Increased VLDL production by the liver or reduced VLDL 
removal are important factors in the development of type IV hyperlipo-
proteinemias. 51 
C. Intermediate density lipoproteins (IDL) 
The IDL's are short-lived lipoproteins derived from VLDL after the 
hydrolysis of the triglyceride of VLDL by the enzyme LPL.51 The 
average percent by weight composition of IDL is 15% protein, 7% free 
cholesterol, 22-26% cholesteryl esters, 17% phospholipids, and 35-39% 
triglycerides.50 It is significant that cholesterol and triglyceride contents of 
IDL are almost the same. The major apoproteins are apo-B and E. 
During the catabolism of one VLDL particle, all constituents, except 
apo-B, are removed from the particle. Of the original amounts, 7% of apo-
C, 20% of triglycerides, 40% of free cholesterol and phospholipids and 
60% of esterified cholesterol are recovered with the IDL particle.50 Each 
IDL particle however, retains the full complement of apo-B present in the 
original VLDL particle. Thus, only one IDL is formed from each VLDL 
particle.56 Apo-Eis responsible for the continued conversion of IDL to 
LDL for hepatic uptake and degradation.51 
Disorders, known as Fredrickson type ill hyperlipoproteinemia, 
occur where there is an abnormal accumulation of IDL because hepatic 
receptors, which have high affinity for apo-E, do not bind or remove 
chylomicron remnants and IDL in a normal manner, due to lack of the 
isofonn known as apo-EIV. 51 
D. Low density lipoproteins (LDL) 
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Low density lipoproteins range in size from 210-250A, are isolated 
between densities 1.019-1.063 g/mL, and display ~-mobility on electro-
phoresis.53 The major lipid constituents by weight are cholesteryl esters 
(47-55%), unesterified cholesterol (10-11 %), phospholipids (28-30%), and 
triglycerides (8-10%).47 The major protein content is apo-B, which 
comprises over 90% of the total LDL protein.47·50 
Low density lipoprotein is the major cholesterol carrying particle 
present in plasma. It is normally formed by hepatic delipidation of IDL by 
hepatic protein lipase. As delipidation occurs, apo-B is unmasked, allowing 
LDL to bind to specific membrane receptors.51 
The degradation of LDL occurs in both peripheral tissues and the 
liver, but the liver is responsible for the catabolism of 70% of LDL in 
normal human subjects. Catabolism is facilitated by both receptor mediated 
and non-receptor mediated pathways, but in normal human subjects, the 
receptor mediated pathway predominates and is responsible for the 
clearance of up to 75% of the plasma LDL pool.57 The sequence of events 
of LDL degradation occur in this order: LDL interacts with high affinity 
receptor sites and .the bound LDL is internalized and subjected to lysosomal 
degradation that ultimately hydrolyzes the apo:.B to amino acids, and the 
esterified cholesterol is hydrolyzed to free cholesterol which enters the 
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cytoplasm.st 
Certain disorders result in either the abnormal absence or abnormal 
accumulation of LDL. In Fredrickson type II hyperlipoproteinemia ( or 
familial hypercholesterolemia), LDL levels increase significantly and are 
characterized by a strikingly high incidence of premature atherosclerosis, 
which tends to cause disease and death at an early age.st Patients with 
familial hyperlipoproteinemia have a defective gene that codes for LDL 
receptor. The elevated plasma levels of LDL cholesterol cause an increased 
uptake of LDL by macrophages and smooth muscle cells of arterial wall 
tissues, resulting in premature atherosclerosis. In the opposite LDL 
dysfunction, no LDL at all has been found in the plasma of patients with 
abetalipoproteinemia. The inherited defect in the disease may be the in-
ability to combine lipid with the B protein. 62 
E. High density lipoproteins (HDL) 
High density lipoproteins are ultracentrifugally isolated in the density 
range of 1.063-1.21 g/mL and have an average percent by weight com-
position of 50% protein, 30% phospholipids, and 20% cholesterol. 50 They 
are sometimes referred to as cx-lipoproteins because they migrate with ex-
globulins during electrophoresis. There are two subclasses based upon 
density differences: HDL2 with densities ranging from 1.063-1.120 g/mL, 
and HDL3 which ranges from 1.120-1.210 g/mL.47 HDL2 has a mean 
molecular weight of 360,000 and is composed of 60% lipid and 40% 
protein, while HDL3 has a mean molecular weight of 175,000, of which 
55% is attributed to the apoprotein. The major proteins are apo A-I and 
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apo A-II which constitute about 90% of the total protein while apo-C form 
the minor components. 50 
The major function of HDL is to transport cholesterol from peri-
pheral tissues to the liver for its catabolism and excretion. In addition, 
HDL plays a major role as a scavenger of lipid and apolipoprotein during 
the normal catabolism of chylomicrons and VLDL. It is also known to play 
an important part as a plasma reservoir for apo-CII. 51 
High density lipoproteins are derived from direct secretions by the 
liver and intestine, transfer from other lipoproteins, and transfer from 
peripheral tissues.14 Little is known about the sites of HDL catabolism. The 
liver and kidney are probably involved.51 
Several factors have been shown to increase HDL concentrations. 
Among these are regular exercise, moderate consumption of alcohol, and 
correction of hypertriglyceridemia.63-64 A particular genetic disorder, 
called Tangier's disease, also exists in which HDL particles are entirely 
absent. The disease is associated with a very low serum cholesterol level 
and the generalized deposition of cholesterol esters in tissues. These 
findings led to the concept that HDL has an important function in 
cholesterol transport. 58 
F. Other lipoproteins 
(1) Lipoprotein (a) ("Sinking" pre-~-lipoprotein or Lp(a)) 
Lipoprotein (a) was discovered in 1963 by Berg65 and became 
important because of its antigenic properties. It is found in human plasma 
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in varying amounts at the density inteIVal of 1.055-1.085 g/mL.50 
Lipoprotein (a) has pre-beta mobility on electrophoresis and is composed 
of 27% protein, 65% lipid and 8% carbohydrates.66-67 The protein moiety 
of Lp(a) lipoprotein was reported to be composed of 65% apoB, 20% of 
Lp(a) apoprotein, and albumin (less than 15% of total protein). Cholesterol 
makes up 41.7% and phdspholipid 19.2% of the total lipid of Lp(a).67 
lmmunochemically, Lp(a) cross reacts with LDL but it differs from LDL 
in both chemical composition and physical properties.50 
Increased plasma concentrations of Lp(a) are associated with 
increased risk of atherosclerosis, but the precise physiologic function and 
the metabolism of Lp(a) remain unknown.68 Apparently, even the near 
absence of Lp(a) from plasma does not cause a deficiency syndrome or any 
kind of disease. 
(2) Lipoproteins occurring in disease states: Lp-X, Lp-Y, and Lp-E 
Lipoprotein-X is an abnormal lipoprotein, composed predominantly 
of free cholesterol and lecithin. It appears in the LDL density range of 
1.006-1.063 g/mL from patients with obstructive jaundice,50 and contains 
about 65% lecithin, 20-30% unesterified cholesterol, and 5% protein. The 
protein moiety is composed of albumin (20-40% of total protein) and apo-
C. 50 Manza to et al. 69 postulated that flowing back of bile into the blood 
stream might represent the actual pathway of Lp-X synthesis. 
Lipoprotein-Y occurs in patients with cholestasis and lecithin 
cholesterol acetyl transferase (LCAT) deficiency.70 It is a triglyceride rich 
LDL, which showed, in addition to apo-C, the presence of apo-B and 
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"lipoprotein B", a lipoprotein particle with higher triglyceride and free 
cholesterol contents than those of normal individuals and an unusually high 
content of apo-C.14 The mechanism of Lp-Y synthesis has. not been 
elucidated completely but it may be related to reduced activity of hepatic 
lipase in liver diseases. 
Lipoprotein-E is a lipoprotein which is very rich in apoE. It was 
first noticed in LCA T deficient plasma by Utermann et al., 71 and was also 
reported in patients with liver disease or secondary LCA T deficiency. The 
mechanism of Lp-E synthesis is not yet known.14 
V. Studies on the Relationship of Lipoproteins with Coronazy Heart 
Disease 
The role of cholesterol and other lipids in the development of 
atherosclerosis is widely recognized. It is known that the two main 
processes of atherogenesis involve cell proliferation and blood lipid in-
filtration.72 Chemical analysis of atherosclerotic plaques from humans 
indicate that on the average it is composed of about one half lipid 
C(?mponents and one half protein. Most of the cells that accumulate in the 
atherosclerotic plaque are modified smooth muscle cells. These have 
undergone changes that have made them less contractile cells in the media 
of the artery and enable them to divide and synthesize collagen and take up 
lipid.73 
The relationship of the various lipids and lipoproteins to CHD and 
their various manifestation have been the major epidemiological objectives 
of the Framingham Heart Study (FHS).18•74-77 It was concluded that 
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LDL-C is positively correlated, while HDL-C is negatively correlated to 
CHD risk. The study determined that VLDL-C is also positively related to 
CHD risk but the relationship tends to disappear when all the lipoprotein 
fractions are considered simultaneously. Other major study programs in 
the United States which include the Lipid Research Clinics Prevalence 
Mortality Follow-up Study (LRCF), the Lipid Research Clinics Coronary 
Primary Prevention Trial (LRC-CPPT), and the Multiple Risk Factor 
Intervention Trial (MRFIT) have also made important contributions 
towards understanding the roles of lipoproteins as CHD risk factors. 
The FHS, started in 1949, was an epidemiological study of cardio-
vascular disease involving a group of 5209 men and women then aged 30 to 
59 years. In 1968, 2815 men and women from the group, ages 49 to 82 
years had their lipids and lipoproteins characterized after an overnight fast. 
The progress of all volunteers had been monitored by means of routine 
biennial medical examinations where possible, and from morbidity and 
mortality data provided by hospitals and other sources.18 
Based on the FHS data, La vie et al. 78 identified the importance of 
HDL-C in preventing CHD. The group observed that CHD is rare when 
HDL-C is high and LDL-C is low. Also, even when LDL-C levels are very 
high, CHD is fairly uncommon if HDL-C levels are 65 mg/dL or more, 
and it is rare when HDL-C levels are as high as 85 mg/dL. On the other 
hand, even when LDL-C levels are very low (~100 mg/dL), CHD is still 
common when HDL-C levels are also very low (~25 mg/dL). Using pooled 
data from four large prospective epidemiologic studies (FHS, LRCF, LRC-
CPPT, and MRFIT), Gordon et al.79-80 concluded that HDL-C represents a 
strong independent risk factor for CHD and that a 1 mg/dL increment in 
HDL-C is associated with a decrease in CHD risk of 2% men and 3% in 
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women. 
Two major hypotheses exist to interpret the role of HDL in 
restricting the development of CHD.19 In the first hypothesis HDL is 
described as a protector against atherosclerosis by its ability to trap excess 
cholesterol from cellular membrane by esterification and to transfer the 
esterified cholesterol to the triglyceride rich lipoproteins that are 
subsequently removed by hepatic receptors. This reverse cholesterol 
transport from the peripheral cells to the liver prevents the deposition of 
cholesterol at sites where excessive cholesterol levels produce athero-
sclerosis. High HDL-C levels will signify a high rate of reverse cholesterol 
transport. In the second hypothesis, it is proposed that HDL does not 
interfere directly with cholesterol deposition in the arterial wall, but 
instead is a measure of the rate of conversion of the TG rich lipoproteins to 
atherogenic remnants. High HDL-C levels then will indicate an efficient 
metabolism of TG-rich lipoproteins and a low production rate of 
atherogenic remnants. 
The Lipid Research Clinics Prevalence Study, done during 1972-
1976 in 10 collaborating North American centers, is another epidemio-
logical study of lipid and other cardiovascular risk factors.79 In 1977, a 
mortality follow-up study (LRCF) was begun by involving all participants 
in the Prevalence Study who were at least 30 years old at that time. 81 The 
primary objective of this study was to acquire data on the prevalence of 
different types of hyperlipoproteinemia in various age and ethnic groups. 
The LRC-CPPT study was a multicenter, randomized double blind 
trial of the efficacy of lowering LDL-C levels in reducing CHD risk in 
3806 asymptomatic middle-aged men with primary hypercholesterolemia 
(~ 265 mg/dL).9•82 Findings of the LRC-CPPT confirmed that reducing TC 
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by lowering LDL-C levels can diminish the incidence of CHD morbidity 
and mortality in men whose high risk for CHD is a consequence of elevated 
LDL-C levels. A decrease of 22.3 mg/dL in LDL-C was associated with a 
16% to 19% reduction in CHD risk. 
Low density lipoprotein is the main carrier of cholesterol from the 
bloodstream. Elevation of plasma LDL-C therefore results in the 
deposition of cholesterol in extrahepatic tissues, including the arterial 
intima, and leads to atherosclerosis. It has been suggested that a more dense 
fraction of LDL is the one responsible for atherosclerosis, although this 
proposal is controversial. 83 Dense LDL is associated with a more athero-
genic type of lipoprotein profile, with increased levels of TG and apo-B 
and lower levels of HDL-C and apoprotein-AI. One explanation for the 
relationship between dense LDL and atherogenesis relates to the increase 
susceptibility of dense LDL to lipid peroxidation. Evidence showed84 that 
oxidized LDL is taken up more rapidly by the arterial cells. Another 
explanation of the atherogenic property of dense LDL is proposed by 
Zilversmit85 and it suggests that the presence of dense LDL may be an 
indicator of a delay in the post prandial catabolism of potentially 
atherogenic, TG-rich remnant lipoprotein. 
The MRFIT study was a randomized, multicenter clinical trial to test 
the effect of a multifactor intervention program on the mortality from 
CHD in 12,866 high risk men aged 35 to 57 years. The subjects were with-
out clinical CHD manifestations but were at high CHD risk (upper 10%-
15%) because of a combination of hypertension, cigarette smoking, and 
elevated plasma cholesterol. 86 Based on the analysis of the MRFIT data, 
Stamler et al. 87 demonstrated that serum TC levels of about 180 mg/dL and 
above are associated with increased risk for middle aged American men, 
and not just levels that are equal to or greater than 220 to 240 mg/dL. 
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In 1985, the United States' National Institute of Health inaugurated 
the National Cholesterol Education Program (NCEP) with the goal of 
planning strategies to reduce the prevalence of elevated plasma cholesterol 
in the United States thereby reducing the incidence of CHO. Since then, the 
NCEP has issued periodic reports developed by its Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel or ATP-I) and its Laboratory Standardization 
Panel (LSP) on the validity of measurements. 88 The second report (ATP-
m presents the NCEP's updated recommendation for cholesterol 
management. The report of ATP-Il is similar to ATP-I in its outline and 
fundamental approach to the treatment of high blood cholesterol although it 
does give more attention to HDL-C as an inverse CHO risk factor.89 ATP-
Il still continues to identify LDL-C as the primary target for cholesterol 
lowering therapy. Dietary therapy remains the initial and principal mode 
of treatment, and drug therapy is reserved for patients at high risk of 
CH0.90 
The guidelines issued by ATP-Il for cholesterol management are as 
follows. 89 All American adults 20 years of age and over should have 
serum TC and HOL-C measured at least once every 5 years. Further risks 
classifications are based on answers to a series of CHO related questions. 
For those without a history of CHD, non-fasting TC and HDL-C 
measurement is sufficient. If any of the following are observed: (1) TC~ 
240 mg/dL, (2) HOL-C ~ 35 mg/dL or (3) TC between 200 to 239 mg/dL 
in association with two or more CHD risk factors, a fasting lipoprotein 
analysis is recommended. Individuals whose LDL-C levels are~ 160 
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mg/dL, and those having LDL-C levels between 130 and 159 mg/dL as well 
as two or more CHO risk factors would be candidates for dietary inter-
vention. Those with existing CHO conditions must submit to fasting 
lipoprotein analysis, regardless of their blood cholesterol level. Low 
density lipoprotein cholesterol values greater than 100 mg/dL would be 
indications for dietary intervention. After an adequate trial of dietary 
modification, consideration might be given to drug therapy if LDL -C 
levels remain 30 mg/dL higher than the initial levels. 89 
Additional risk factors identified and expressed in ATP-II are:89 (1) 
age; male 45 years and older; female 55 years and older or having 
premature menopause without estrogen replacement therapy; (2) family 
history of CHO; (3) cigarette smoking; (4) hypertension ( blood pressure 
of 140/90 mm Hg and higher) or use of antihypertensive drugs; (5) HOL 
cholesterol level less than 35 mg/dL; and (6) diabetes mellitus. 
CHAPTER ill 
REVIEW OF ANALYTICAL METHODS FOR CHOLESTEROL AND 
LIPOPROTEIN DETERMINATION 
I. Methods to measure serum total cholesterol 
A. Colorimetric methods 
Interest in the determination of cholesterol originated in the late 19th 
century, and since then many methods have been developed. A compre-
hensive review of colorimetric methods for cholesterol determination was 
published by Zak and Ressler91 in 1955 and by Tonks92 in 1967. 
The first attempt to measure cholesterol by color determination was 
made by Liebermann93 in 1885 and applied by Burchard94 in 1890. In 
1910, Grigaut95 introduced a procedure for the quantitative estimation of 
cholesterol based on the Liebermann-Burchard (L-B) reagent. At almost 
the same time, Windaus96 employed a microgravimetric analysis for the 
determination of cholesterol using digitonin as the precipitating agent. 
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The L-B color reagents consist of a mixture of acetic anhydride and 
concentrated sulfuric acid, and occasionally glacial acetic acid. The color 
reaction was studied extensively and a number of modifications appeared 
which improved upon some of the drawbacks of this reaction. Among these 
drawbacks are its complexity and sensitivity to many variables, e.g. the 
composition of the mixture, the amount of water (if any) in the final 
reaction mixture, the solvent used, the reaction time and temperature, the 
effect of light, the wavelength at which the color is measured, and the 
occurrence of interfering substances such as bilirubin and unreacted 
digitonin. Neither the reagent nor the color of the final product is 
particularly stable.92 
A series of modifications involved different extraction procedures. 
Autenrieth and Funk,97 for instance, digested blood with a base and then 
extracted the cholesterol with chloroform or ether before carrying out the 
L-B reaction. Bloor98 extracted cholesterol from the blood using an 
alcohol-ether mixture, evaporated the solvent, re-dissolved the residue in 
chloroform and ran the L-B reaction in the choloroform solution. In yet 
another procedure, cholesterol is extracted into an acetone-alcohol mixture 
and precipitated as the digitonide salt.99 This is re-dissolved in acetic acid 
which is used as the solvent for the L-B reaction. In the Abell et al. 100 
method, the work-up involves hydrolysis of cholesterol esters with 
alcoholic potassium hydroxide, extraction of the free cholesterol into 
petroleum ether, before measuring it by the L-B reaction. 
To improve upon the reagent stability, Huang et al. 101 used a 
mixture consisting of glacial acetic acid, acetic anhydride, and sulfuric acid 
plus anhydrous sodium sulfate. Huang's procedure could be applied directly 
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to serum without using prior extractions. Trinder102 modified the reagent 
to a mixture of acetyl chloride and sulfuric acid. The color produced in 
this reaction was said to be much more stable than the colors produced by 
modifications of the L-B reaction. 92 
Another group of color reagents for cholesterol determination uses 
p-toluene sulfonic acid (p-tsa) and related reagents. The reagents and the 
resultant colors are more stable compared to the L-B reaction.92 A 
mixture of glacial acetic acid, p-tsa, and acetic anhydride, used by Pearson 
et. aI.103 in the direct analysis of serum cholesterol, was modified by (a) 
including sulfuric acid;104 and (b) substitution of p-tsa with dimethyl-
benzene sulfonic acid 105 or sulfosalicylic acid.106 
Salts of iron (ill) in concentrated sulfuric acid were the bases for 
other alternative color reagents. Zlatkis et al.107 chose the metal chloride 
plus acetic acid. Sensitivity, precision and stability were improved using 
phosphoric acid in dissolving ferric chloride instead of acetic acid; 108 using 
ferric chloride in a mixture of phosphoric and perchloric acid; 109 using 
ferric chloride, glacial acetic acid and citric acid;110 and finally ferric 
perchlorate, ethyl acetate and concentrated sulfuric acid.111 
Another color reagent based upon a metal salt substrate was 
developed in 1910 by Tschugaeff.112 The reagent is more sensitive than the 
L-B reagent and has been used by several scientists for cholesterol 
determination in blood.112-116 Flourometric detection was also used as an 
alternative to absorbance detection in the L-B 117 and Tschugaeff 
reactions.118 
B. Enzymatic methods 
The high selectivity provided by enzymes have also been used to 
advantage in cholesterol determinations in steps that are preliminary to 
30 
absorbance detection. Cholesterol dehydrogenase was used by Flegg119 to 
oxidize cholesterol to ll 4- cholestenone and the absorbance was measured at 
240 nm. Richmond 120 isolated cholesterol oxidase and applied the purified 
enzyme to the direct assay of cholesterol in saponified serum. The 
hydrogen peroxide produced in the reaction of cholesterol oxidase with 
serum cholesterol was reacted with xylenol orange and quadrivalent 
titanium and the absorbance of the complex was measured at 550 nm. The 
method of Allain et al.121 involved the use of three enzymes to determine 
total cholesterol in serum. The third enzyme hydrolyzes the cholesterol 
esters and eliminates the saponification step. 
The hydrogen peroxide produced by the action of cholesterol oxidase 
has been coupled with a numbe.r of co-reagents to produce a stable color. 
Allain et al.121 used 4-amino-antipyrine and phenol with absorbances 
measured at 500 nm. Huang et al.122 chose homovanillic acid in the 
presence of peroxidase to form a highly fluorescent compound. 
Papastathopoulos and Rechnitz123 reacted the hydrogen peroxide with 
iodide in a molybdenum (Vn - catalyzed indicator reaction and monitored 
the change in iodide concentration with an ion selective membrane 
electrode. 
Flow injection analysis (FIA) together with enzyme immobilization 
has been used for cholesterol determinations. Combinations of these two 
techniques offers several advantages that include selectivity, low cost per 
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analysis, small sample consumption, and short analysis time. Methods have 
been proposed for the determination of cholesterol using FIA and 
immobilized enzyme with amperometric detection 124-127 as well as 
photometric and fluorometric detection.128 Petersson et aI.129 and 
Malavolti et al.130 developed flow injection systems coupled with luminol-
hydrogen peroxide chemiluminescence detection. Use of a fiber optic 
cholesterol biosensor was reported by Trettnak and Wolfbeis131 and the 
detection was based on immobilized cholesterol oxidase and an oxygen-
quenched fluorescent reaction. Krug et al. 132 investigated the feasibility of 
a photometric method using the fiber optic detection approach employing 
the dye 2-2' -azino-bis-(3-ethyl-benzthia-zoline-6-sulfonic acid) 
diammonium salt. A cholesterol sensor was also fabricated by Dong 
et al.133 based on electrodeposition of palladium and enzyme 
immobilization on glassy carbon electrode. The hydrogen peroxide 
produced is monitored by measuring the current of peroxide oxidation 
electrocatalyzed by dispersed palladium particles. 
C. Chromatographic methods 
Chromatographic methods have also been adapted to determine 
cholesterol in human serum. Kritchevsky et al. 134 separated the cholesterol 
by thin layer chromatography, scraped the cholesterol spot into a test tube, 
charred it with concentrated sulfuric acid and quantitated by determining 
the absorbance at 375 nm. Several groups have used gas-liquid chromato-
graphy.135·137 Prior work-up schemes involve saponification, extraction, 
and sometimes derivatization of cholesterol from the serum. Duncan 
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et al.138 prepared the sample according to Abell-Kendall 101 and used 
reversed phase liquid chromatography with detection at 200 nm. Nomura 
et al.139 determined cholesterol by supercritical fluid chromatography on 
an inert octadecylsilane-silica gel column using supercritical carbon dioxide 
as mobile phase. The eluent is monitored simultaneously with flame 
ionization and ultraviolet absorption detector. 
D. Mass spectrometry methods 
The use of isotope dilution-mass spectrometry (ID/MS) in the 
determination of cholesterol in serum was first reported by Bjorkhem 
et al.140 in 1974. Deuterium-labelled cholesterol ([2,2,3,4 - 2H4 ]-
cholesterol) was added to a fixed amount of serum. The ratio of the 
molecular ions (m/z 386 and 389) measured by GC-MS was used for the 
determination. Gambert et al.141 separated cholesterol on a capillary 
column and used the [3,4 - 13C] isotope of cholesterol because the non-
radioactive 13C isotope eliminates radiolysis reactions, exchange processes 
or isotopic effects. Mass spectrometry was used in the chemical ionization 
mode leading to simple fragmentation with a greater relative abundance of 
the high mass ions. Cohen et al.142 added cholestero-d7 [cholest-5-en-
25,26,26,26,27,27, 27-d1-3-ol (38)] to the serum and added a 
derivatization step (trimethyl silyl ether derivative). The intensity ratio of 
molecular ions at m/z 465 and 458 was followed by GC-MS. Takatsu and 
Nishi 143 used ID/MS with high performance liquid chromatography instead 
of GC. The same authors developed a liquid chromatography-atmospheric 
ionization-MS 144 for serum cholesterol determination. 
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E. Other methods 
A recent approach that uses near infrared reflectance spectrometry 
detection to measure serum cholesterol was described by Peuchant et al. 145 
in 1987. Preliminary spectral calibration is performed using human sera 
whose cholesterol concentrations are measured by a reference chemical 
analysis. Calibration makes it possible to select wavelengths that are 
characteristic of the matrix and its composition. Calibration constants, 
obtained from regression calculations, are used to quantify serum 
cholesterol according to a mathematical equation. The determination is 
performed directly on serum without prior extraction or added reagent. 
Results are obtained in less than one minute. 
IL Methods for serum lipoprotein separation 
A. illtracentrifugation 
Differences in the hydrated densities among the lipoproteins make it 
possible to do fractionation by ultracentrifugation. The Center for Disease 
Control (CDC) Primary Reference Method for determining lipoprotein 
classes is based upon separation by ultracentrifugation. The method is time 
consuming, expensive, and therefore not suitable for large scale use.146 Its 
use is restricted to specialized lipid research laboratories. Various types of 
ultracentrifugation have been employed in lipoprotein analysis. 
The separations of lipoprotein classes by sequential differential ultra-
centrifugation involves repeated ultracentrifugation ( depending on the 
desired separation) after progressively raising the solvent density. This 
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method was first reported by Havel et al.147 and De Lalla and Gofman 148 
in the 1950's. Relatively large quantities of plasma can be processed at one 
time and purification of the lipoproteins from other proteins of density 
> 1.21 g/mL is excellent.149 However, sequential ultracentrifugation can 
cause some structural alteration perhaps due in part to long periods of 
exposure to the high salt concentrations and high g forces involved. 
The beta-quantification method which has been accepted as a 
Reference Method,24 is a combination of ultracentrifugation and pre-
cipitation steps. A single ultracentrifugation step is performed, separating 
the plasma at its own density of 1.006 g/mL. After spinning at 109,000 x g 
for 18 hours, VLDL and chylomicrons float to the top leaving IDL, LDL 
and HDL in the infranate. The supernatant and infranatant fractions are 
separated by a tube slicing technique. The cholesterol concentration of 
plasma, the infranate and the HDL fraction (obtained by chemical preci-
pitation of LDL and IDL in the infranate with heparin-manganese) are 
measured by the Abell-Kendall method.100 Very low density cholesterol is 
calculated as plasma cholesterol minus the total infranatant cholesterol 
while LDL-C is total infranatant cholesterol minus HDL-C. Additional 
ultracentrifugation steps are sometimes performed on the infranate to 
individually separate sub-classes of different densities. Density adjustment 
to 1.019 g/mL is used to float IDL, adjustment to 1.063 g/mL will float 
LDL and adjustment to 1.21 g/mL isolates HDL.24 
Density gradient ultracentrifugation is a different procedure that 
gained widespread usage in the mid-1970's when Redgrave et al.150 
developed the four step density gradient technique to separate plasma 
lipoproteins. This technique uses solutions of different densities which are 
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carefully layered into each tube along with the sample. After ultra-
centrifugation to equilibrium, each of the lipoproteins will have migrated 
into its respective isopycnic density region. The method can separate the 
lipoprotein classes in a single centrifugation step but incomplete separation 
may introduce error.151 
B. Selective precipitation 
Precipitation methods were primarily developed in the laboratory of 
Burstein 152 whose purpose was to isolate lipoproteins from large serum 
sample volumes or to eliminate LDL-C and VLDL-C from small sample 
volume in order to determine HDL-C. These methods are fast, simple, and 
inexpensive which accounts for their popularity .153 Various precipitating 
agents have been studied for the precipitation of the serum lipoproteins. 
A polyanion such as heparin, either alone or associated with a 
bivalent cation, selectively precipitates the various lipoprotein classes. At 
neutral pH and in the presence of a bivalent cation, the ability to precipitate 
depends upon the relative lipid content. At slightly acid pH, and in the 
absence of bivalent cation, precipitation is related to the dominant 
apoprotein. 154 Low density lipoprotein is the major precipitate in the pH 
dependent procedure and the minor precipitate in the metal ion dependent 
procedures. 
Low density lipoprotein is also precipitated by high molecular 
weight sulfated polysaccharides at either neutral or slightly alkaline pH. 
Oncley et al.155 reported that dextran sulfates with molecular weights over 
a million, precipitate LDL and VLDL but do not precipitate either chylo-
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microns or HDL. 
Highly charged anions precipitate LDL and VLDL fractions almost 
completely. Among these are sodium phosphotungstate (2Na2P205 
12W03,l8H20), ammonium paramolybdate ((Nlii)6Mo7024, 4H20), and 
two smaller monomeric bivalent anions, sodium tungstate (Na2W04, 
2H20) and sodium molybdate (Na2Mo04, 2H20).154 
One step precipitations of serum lipoproteins can also be 
accomplished with any of the following reagents: (a) polyphosphates and 
bivalent cations, (b) tetracyclines and bivalent cations, ( c) anionic 
surfactants and bivalent cations, ( d) anionic surfactants and polycations 
(protamine sulfate), and (e) cationic surfactants and a polyanion (heparin). 
In each of these associations, the reactants bear opposite charges, and the 
anion-cation interaction results in the formation of insoluble salts.154 Non-
ionic linear polymers of high molecular weight that are freely soluble in 
water, such as polyvinylpyrrolidone, polyethelene glycol (PEG) and 
dextran, have also been used.154 
Several studies24·146.l53·156-158 have assessed the performance of the 
different precipitating agents for lipoprotein analysis. Wiebe and Smith 155 
compared six precipitating agents used in HDL analysis. They evaluated 
heparin-MnCh at two different concentrations (46 and 92 mmol/L), 
dextran sulfate-MgCh using two different molecular masses of dextran (Mr 
50,000 and 500,000), sodium phosphotungstate-MgCh, and PEG 6000. 
Their results showed that precipitation with heparin-MnClz (92 mmol/L) 
and PEG gave similar results while dextran sulfate-MgCh (Mr 500,000) 
had the largest proportional and constant bias. All the methods produced 
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comparable result in the low HDL cholesterol range (25 to 35 mg/dL) but 
biases were significant at high concentrations. The increased bias in the 
upper HDL cholesterol range may be due to increased heterogeneity of 
HDL and the different mechanisms involved in forming the insoluble 
complexes between lipoproteins and the various precipitating agents. 153 
Warnick et al.156 reported that dextran sulfate (50)-Mg+2, heparin-Mn+2 
(92 mmol/L) and phosphotungstate-Mg+2 give similar results, while 
heparin-Mn+2 (46 mmol/L) and PEG at two different concentrations (75 
and 100 g/L final concentration) gave slightly higher values for HDL 
cholesterol. 
C. Electrophoresis 
Differences in size and charge among the lipoproteins are the bases 
for separation by electrophoresis. The net charge on a lipoprotein molecule 
results from the balance of positive and negative charges on the terminal 
and side chain amino acid residues, and to a small extent from the phospho-
lipids that are not in the zwitterionic form at electrophoretic pH.159 
Electrophoretic separation of lipoproteins provides for only 
qualitative analysis of the particle distribution.160 It is possible to quantify 
the bands based on the relative intensities of their stained electrophoretic 
bands determined by scanning densitometry. However, dye uptake by each 
lipoprotein is variable and correlates poorly with concentration.160 Studies 
have also suggested that many of the electrophoretic methods do not 
achieve acceptable precision.161 
Early electrophoretic methods used a liquid phase without supporting 
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media (free electrophoresis). Although this technique is no longer widely 
used, it gave valuable information to early investigators. The technique has 
been abandoned since then and has led to the development of electro-
phoresis on fixed media. Zone electrophoresis is considered more 
advantageous since it requires simpler equipment.162 Media that have been 
used as supports include starch granules, 163·164 paper, 165 cellulose 
acetate, 166 agarose, 167·168 and polyacrylamide geI.169·170 
D. Chromatography 
Chromatographic separations of lipoproteins are based on size 
differences. High performance liquid chromatography (HPLC) has been 
extensively used in the laboratory of Okazaki171-175 in the analysis of lipo-
protein classes. They developed an HPLC separation method for serum 
lipoprotein using columns designed for gel permeation chromatography. 
Quantitation of cholesterol was performed using an enzymatic reaction and 
absorbances were monitored at 280 nm and 550 nm for protein and 
cholesterol, respectively. The method successfully separated VLDL, LDL, 
HDL2, and HDL3. It is very simple and gives a direct determination of the 
fractions in less than 50 minutes without any pretreatment.171 Other 
components of the lipoprotein can also be determined with appropriate 
reagents for selective detection.174·175 Chromatographic methods are 
relatively expensive and at present are largely restricted to specialized 
research laboratories.160 
Lipoprotein separations have also been made using agarose column 
chromatography.176·177 The method is gentle and non-destructive, being 
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simultaneously preparative and analytical and capable of providing an 
adequate recovery of lipoproteins after separation. The major drawbacks 
are long analysis time (24 hours) and the inability to obtain homogeneous 
lipoprotein fractions. 176 Hydroxyapatite column chromatography178 has 
been used for the separation of subfractions 2 and 3 from HDL isolated by 
preparative ultracentrifugation. 
E. Immunochemical methods 
Because of differences in the protein moieties among the lipoprotein 
classes, immunochemical methods have been developed for their 
quantitation. The ability of proteins to stimulate the production of specific 
antibodies enabled investigators to identify and quantify proteins in 
mixtures, even at very low concentrations. Immunochemical methods are 
more sensitive, selective, reproducible, and potentially more adaptable to 
automation than non-immunological procedures.51 Drawbacks are the 
significant problems associated with producing antisera and in the 
standardization of lipoprotein assays. Also, immunological cross reactivity 
makes quantitative immunological analysis of specific lipoprotein fractions 
in whole plasma difficult .58 
The introduction of specific antisera for the apoproteins enabled the 
development of various types of immunoassays leading to the quantification 
of the protein moieties of VLDL, LDL, and HDL, together with their 
subclasses. These immunochemical techniques include, radial immuno-
diffusion, 179 electroimmunoassay in agar or agarose gel, 179 radio-
immunoassay, 180 immunonephelometry,181 enzyme linked immuno-
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assay, 182•183 and fluorescence immunoassay.184 
III. Proposed alternative method provided by this study 
Despite the presence of many analytical methods for cholesterol and 
lipoprotein determinations, the Laboratory Standardization Panel continues 
to encourage the development of new methods particularly for LDL-C and 
HDL-C determinations that is applicable for routine use in the clinical 
laboratories.24-25 The method should pass the requirements set by LSP in 
terms of precision and accuracy. 
This study had as a goal the development of a method that measures 
the three major lipoprotein fractions simultaneously with an acceptable 
accuracy and precision. Measuring the lipoprotein fractions simultaneously 
reduces the analysis time and is applicable for routine use. The applicability 
of the method to measuring cholesterol in hypertriglyceridemic samples 
was evaluated. 
CHAPTER IV 
EXPERIMENTAL 
A. Sources of Serum Samples 
Serum samples for this work were provided by four different 
laboratories: Oklahoma State University Wellness Center (UWC); 
Stillwater Medical Center (SMC); Roche Biomedical Laboratories (RBL), 
Kansas City, Missouri; and University of Cape Town Medical School 
(UCT), South Africa. 
Samples provided by UWC were from volunteers who requested a 
lipid profile from the Oklahoma State University. No attempt was made to 
select subjects according to demographic classification, and no demo-
graphic data were collected. Subjects were instructed to report to the 
Wellness Center laboratory having fasted for at least 12 hours. A venous 
blood sample was drawn from the arm of each subject and placed into two 
Vacutainertm red stoppered serum separation tubes. Serum separation tubes 
have a floating gel to aid in separation of red cells from serum. After 
letting the serum stand at room temperature for about 30 minutes, it was 
centrifuged at 5,000 rpm for ten minutes in a table top clinical centrifuge 
(Roche Biomedical Laboratories VanGuard 6000). One separation tube was 
taken to the Oklahoma State University Department of Chemistry, for 
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measurement by the alternative method. Samples were transferred into new 
10 mL glass vials with a screw cap. The second separation tube was 
collected by Roche Biomedical Laboratories personnel for measurement at 
its Kansas City, Missouri regional laboratory. 
Samples from SMC and RBL were exclusively high triglyceride 
specimens (TG >250 mg/dL). This figure is much lower than the normally 
accepted cut-off level of 400 mg/dL used for the Friedewald formula.21 
Measurements by SMC and RBL were made in-house using one of the 
standard routine enzymatic methods. After the serum lipids had been 
measured, the residuals of the samp1es were collected and sent to OSU 
Department of Chemistry. 
The majority of the UCT samples were categorized as having lipid 
disorders (Type III and familial hypercholesterolemia) but a few were 
normal samples. Splits from these venous samples were shipped overnight 
to OSU. Lipoprotein fractions were separated in-house by ultracentri-
fugation, and split portions from these fractions were also shipped to OSU. 
Cholesterol and TG measurements were made at UCT on the fractions after 
separation. 
The size of the sample pool is currently around 650 samples and is 
almost equally divided between normal and high triglyceride levels. Some 
samples were hemolyzed in the collection process and some were creamy in 
appearance, neither of which produced an observable interference in the 
method. Samples were not categorized according to gender, race, age, etc. 
Sample collection and storage conditions before receipt were not 
standardized, nor was the interval of time that passed between making the 
tests in the different laboratories. When the samples were received they 
were kept in the refrigerator maintained at 4 °C and were equilibrated to 
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room temperature for at least 30 minutes before analysis. Serum samples 
appear to be stable for at least 2-3 months when stored in the refrigerator. 
Replicate measurements were made in our laboratory to evaluate the 
imprecisions in the measured spectra that would result from the combined 
effects of the sampling procedure, and the chemistry of the color reaction. 
B. Analytical Methods Used in Independent Laboratories 
The laboratories at Roche Biomedical and SMC regularly use one of 
' 
the current routine commercial methods to measure lipid profiles. The 
Olympustm AU560 and Technicontm Chem-I clinical autoanalyzer are 
preferred by RBL and SMC, respectively. Three independent 
measurements are made in order to obtain a lipid profile. Total cholesterol, 
HDL-C, and TG are measured directly by enzymatic methods. 
The enzymatic method for determination of cholesterol is based on 
the method developed by Allain et al.121 and uses a color derivatization 
reaction described by Trinder.185 The enzymatic reactions involved are as 
follows: 
Cholesterol Esters + H20 Cholesterol • Cholesterol + Fatty Acids 
Est erase 
Cholesterol 
Cholesterol+ 02 ~ Cholest-4-en-3-one + H20 2 Oxidase 
2H O 4 Amin . . H dr b 1.c Peroxidase• 2 2 + - · oantlpynne + p- y oxy enzenesu 1.onate 
Quinoneimine Dye + 4H20 
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The quinoneimine dye produced is measured by its absorbance at 500 nm. 
Although the quinoneimine dye is not structurally related to cholesterol, 
the absorbance intensity of the colored product is proportional to the 
amount of cholesterol. For the HDL-C determinatons, the same enzymatic 
processes were used after VLDL-C and LDL-C were selectively removed 
by precipitation reaction with a prepared aliquot of dextran sulfate-Mg+2• 
The VLDL-C fraction is calculated as equal to one-fifth of the TG value as 
long as TG is not > 400 mg/dL. The routine method for TG determination 
also involve a four step.enzymatic reaction. The LDL-C levels are 
estimated using the Friedewald formula, 21 
LDL-C = TC - ( HDL-C + TG/5 ). (eq. 1) 
For samples with TG > 400 mg/dL, only TC and sometimes HDL-C results 
would be reported by the outside laboratories. 
Lipid profiles of samples from UCT were determined by sequential 
ultracentrifugation. Solutions of KBr were added for density adjustments. 
Adjustment to 1.006 g/mL is used to float VLDL-C and chylomicrons; 
adjustment to 1.019 g/mL is used to float IDL-C; adjustment to 1.063 g/mL 
will float LDL-C and adjustment to 1.21 g/mL isolates HDL-C.24 
Cholesterol and TG levels for each fraction were measured by the same 
enzymatic methods discussed earlier. 
C. The Proposed Alternative Method 
The method is based upon a color production reaction. The color 
reagent used in this work has evolved from that first described by 
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Chugaev and Gastev .112 In its original form, the reagent was a 2: 1 mixture 
of a solution of 20% w/v ZnCh in glacial acetic acid combined with 98% 
acetyl chloride. The reagent was used succesfully to measure only total 
cholesterol levels.113-116 This reagent was also used in trials to measure the 
cholesterol distribution among the lipoprotein fractions using circular 
dichroism (CD) spectropolarimeter as the detector.26 In the CD study, a 2-
ml aliquot of the reagent was added to 50 µL of serum. After 8 minutes of 
incubation at 67°C, the solution was cooled to room temperature and 1 mL 
of chloroform was added followed by CD measurements from 625-325 
nm. Results of the CD study showed that while CD is capable of 
discriminating HDL-C from the low density fractions, distinction between 
VLDL-C and LDL-C was not possible. 
In a subsequent study, 186 CD was replaced by absorption detection. 
The ZnCh concentration was increased to 35% w/v and the volume ratio of 
the solvents was inverted so that acetyl chloride was in a 100: 1 excess over 
acetic acid. This modification produced signals of increased intensity and 
eased some of the problems with protein precipitations when reagent and 
serum were mixed. Incubation conditions remained the same but, because 
of the increased sensitivity, the sample size was decreased to 20 µL. Two 
reagents are kept separate before being added to the serum, which is 
inconvenient for routine screening work. Experimental conditions still 
require an 8 minute incubation period at 67°C, which is 14°C higher than 
the boiling point of acetyl chloride, which is now the solvent in excess. 
The reagent that has evolved during this study is a one reagent 
system. Glacial acetic acid was eliminated altogether and the metal salt was 
changed to Zn(Cl04)2·6H20 (Johnson-Matthey or G. Frederick Smith). 
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The perchlorate salt dissolves in 98% acetyl chloride (Sigma or Aldrich) 
directly and is used at a concentration of 0.50 M. Traces of insoluble 
material, probably ZnO, are conveniently removed by centrifugation for 
10 minutes. The reagent is prepared when needed and stored in a tightly 
sealed amber glass container. A major advantage of these modifications is 
that color is produced at room temperature which significantly reduces the 
hostility of the reaction conditions. 
The reagent to serum volume ratio was maintained at 100:1. Tests 
are conveniently done on samples as little as 10-µL, making the method 
applicable, in principle, to a serum sample as small as a finger-stick. Serum 
and reagent are added, in that order, to a glass vial and shaken by hand for 
15-30 seconds. Proteins precipitated on adding the reagent are removed by 
centrifugation (Fisher Microcentrifuge Model 59 A; speed setting at 9 .0) 
for 3 minutes. Color begins to develop at ambient temperatures 
immediately after mixing. The supernatant is transferred to a cuvet with a 
pathlength of 1 cm. Absorbance spectra are measured after 15 minutes 
from the time of mixing by making five spectral passes from 350-7 50 nm 
using a Hewlett-Packard 8452A diode-array spectrophotometer equipped 
with a temperature controller (25.0 ± 0.1 °C). The wavelength range is 
wider than it was in prior work186 which facilitates the measurement of 
lipid profiles, especially for those with high TG levels. 
A kinetic study of the color reaction shows it to be 98% complete 
after a period of 15 minutes, which is the time used for routine 
measurements. The ultimate color is stable for at least an hour. The 
function of the Chugaev reagent is not atypical of Friedel-Crafts reagents. 
Most likely, therefore, the mechanism will involve dehydration and 
dehydrogenation steps. Friedel-Crafts reagents generally consist of an acid 
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halide and a Lewis acid catalyst. We found that the zinc chloride, acetate, 
and perchlorate salts, in combination with acetyl chloride will produce the 
colored product, as will perchloric acid. Acetic acid, needed to solubilize 
·, 
the zinc chloride for the original Chugaev reagent, appears to retard the 
reaction rate which accounts for the higher incubation temperature when it 
is present. Like zinc perchlorate, zinc acetate dissolves directly in acetyl 
chloride eliminating the need for glacial acetic acid. The perchlorate salt 
was chosen over the acetate because the latter formed a yellow solution 
with acetyl chloride after several hours. 
From a mechanistic study of tlie Chugaev reagent, 187 it was 
proposed that the color is a product of extended conjugation. Similar 
mechanisms were proposed for the Liebermann-Burchard188 and Zak189 
reactions. The Chugaev reaction was also run on a number of structurally 
related steroids.190 Those that produce color were also found to have 
antirachitic activity, implying a structural similarity between the product 
and vitamin D. In other words, the B-ring of the cholesterol template 
would open at C-10, Figure 2, stimulating dehydrogenation throughout 
rings C and D. 
Figure 2: Proposed product of the color reaction.187 
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D. Comparison of Data Analysis Methods 
Determining the concentration of an analyte involve two steps: a 
calibration step and a prediction step. In the calibration step, a 
mathematical equation is developed that define the relationship between 
instrument response, A, and the analyte concentrations, C.191 The 
calibration equation vary in complexity depending upon the extent of 
linearity or non-linearity of the correlation. Once the calibration equation 
has been established, it will be used to predict the concentration of future 
samples. There are several approaches in obtaining the calibration 
equation. 
Univariate Approach 
This approach to calibration typically uses just one A variable (e.g. 
absorbance at one wavelength) to determine the calibration equation. The 
calibration equation is obtained by measuring the absorbances of a series of 
solutions of known concentrations for a standard reference material. In 
many instances, the entire spectra is obtained but in univariate data analysis 
only one absorbance (usually the maximum absorbance) will be used. The 
additional information contained in the spectrum remains unused. The 
absorbance data are then plotted against concentration to construct a typical 
Beer's law working curve. Simple linear regression is used to find the 
statistically best straight line and the corresponding linear calibration 
equation. 
The univariate approach assumes that the measurement method is 
specific or selective and that no other matrix constituents influence the 
measurement signal. These conditions are not always fulfilled unless the 
samples are purified and stabilized prior to analysis. Interferences may 
affect the measurements and make them unsuitable for univariate 
prediction.192 For complex mixtures, separation of the desired analyte 
from the interferences is a pre-requisite for successful calibration and 
prediction. 
Multivariate Approach 
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Multivariate calibrations, in contrast, combine several different 
variables ( e.g. light absorbance at different wavelengths) in developing the 
calibration equation. As a consequence interferences can be modelled 
and/or eliminated and outliers detected.193 One does not necessarily need 
the reference materials for calibration. Instead, one reverts to making a 
broad selection of real samples. The emergence of microcomputer in the 
laboratory has led to the increased usage of multivariate calibration in data 
analysis, and it has provided the analytical chemist with the ability to 
accumulate vast amounts of data in a relatively short period of time. 
Multivariate calibration can reduce the need for sample preparation 
in chemical analysis because various interferences can be accounted for in 
establishing the calibration equation. Complete separation of the 
interferences is not a prerequisite compared to the univariate approach. 
After calibration, one is able to replace cumbersome, slow chemical 
analysis methods by simple, fast instrumental measurements, provided that 
the unknown samples belong to the same type of samples used for 
calibration. 194 
Direct or indirect calibration can be used for multivariate data 
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analysis. Direct multivariate calibration involves prior measurements of the 
spectra for pure forms of the individual constituents. In the indirect 
approach, one foregos the need for the spectra of the pure components. A 
"representative" set of "reference samples" with measured values for both 
spectrum and concentration is used for the estimation of the calibration 
coefficients.193 
Several multivariate methods are encountered in the literature.191-
196 Only multiple linear regression (MLR), principal component analysis 
(PCA), principal component regression (PCR), and partial least squares 
regression (PLS) are discussed in subsequent sections. 
Multiple Linear Regression (MLR) 
Multiple linear regression is the simplest of the multivariate 
calibration method. The goal of MLR is to find the linear combinations of 
the response variable (aj) in the response matrix A such that the model 
estimates ( Oi) of the values in the concentration matrix C in the calibration 
set, given by, 
j 
Oi,k = 1: aij · Sjk 
j=l 
(eq. 2) 
are as close to the known values of C as possible.195 The regression 
coefficients, Sjk are estimated by linear regression with the error term, 
expressed as 
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k 
Error = :r. :r. ( Cik - Oi,k ) 2 (eq. 3) 
k=l i=l 
is kept to a minimum. The general relationship between the concentration 
matrix C and response matrix A given by MLR is 
C=AS+E (eq. 4) 
where S is a matrix of regression coefficients and E is a matrix of errors 
associated with the MLR model. 
Multiple linear regression is reasonable when dealing with well 
defined systems (responses are linear, no interfering signals, no analyte-
analyte interactions, low noise and no collinearities ).195 All the 
information in the response matrix A is used to establish the mathematical 
relationship between A and C regardless of whether or not it is relevant in 
describing the true relationship. 
Principal Component Analysis (PCA) and Principal Component Regression 
(PCR) 
The first step in PCR is PCA. The American Society for Testing and 
Materials define PCA as " a mathematical procedure for resolving sets of 
data into orthogonal components whose linear combinations approximate 
the original data to any desired degree of accuracy. As successive 
components are calculated, each component accounts for the maximum 
possible amount of residual variance in the set of data. In spectroscopy, the 
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data are usually spectra, and the number of components is smaller than or 
equal to the number of variables or the number of spectra, whichever is 
less."196 
Principal component analysis searches for a few uncorrelated linear 
combinations of the original variables that capture most of the information 
in the original variables.197 Geometrically, the first principal component is 
the line of closest fit to the n observations in the p dimensional variable 
space. It minimizes the sum of the squared distances of the n observation 
from the line in the variable space representing the first principal 
component. The second principal component is a line of closest fit to the 
residuals from the first principal component. 197 The process goes on until 
all the variations in the variables are accounted for, but the first few 
components account for most of the variation. 
Algebraically, the first principal component U1 (also known as 
scores or factors) for a given measured variables A, is a linear 
combination of the variables in A given by 
p 
U1=Y11·A1+Y12·A2+ ... +Y1p·Ap= 1: YH·Ai (eq.5) 
i=l 
such that the variance of the first principal component is maximized. The 
coefficients Y are referred to as "weights" and are always scaled so the sum 
of the squared weights is equal to one198 
p 
1: (Yli)2= 1. (eq. 6) 
i=l 
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Since the variance of U 1 is maximized, the sum of the squared correlations 
p 
I: ( r u,Ai )2 is also maximized. 
i=l 
The second principal component U2 involves finding a second weight 
vector Y 2 such that the variance of 
p 
U2 = Y 21 · A1 + Y 12 • A2 + ... + Y lp • Ap = I: Y 2i · Ai 
i=l 
(eq. 7) 
is maximized subject to the constraints that it is uncorrelated with the first 
p 
principal component and I: ( Y 1i )2 = 1.197 This process can be continued 
i=l 
until as many components as variables have been calculated. 
The main parameters resulting from a principal component analysis 
are the matrix of the weighted vector Y that is associated with each 
principal component U and its associated variance A. The correlations 
(loadings) of the measured variables with a particular component, can be 
obtained by multiplying all the elements in the weight vector by the square 
root of the variance A of the associated principal component.197 
The second step of PCR uses MLR to fit the concentration matrix C 
of the calibration samples onto the scores or principal component matrix 
U .195 This can be represented by 
US = C (eq. 8) 
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where S is the matrix of regression coefficients obtained by MLR. 
For predicting the concentration of unknown solution, one uses the 
Y and S matrix. The response of the unknown sample Aun1c is multiplied 
by Y to obtain Uun1c and then Dunk is multiplied by S to yield tun1c , the 
estimate of the concentration of the analytes in the unknown samples.195 
Partial Least Squares Regression (PLS) 
The pioneering work in PLS was done in the late sixties by H. Wold 
in the field of econometrics. Chemical applications were pioneered by the 
group of S. Wold and H. Martens in the late seventies.199 Partial least 
squares regression is based on H. Wold's general PLS principle in which 
complicated, multivariate problems are solved by a sequence of simple 
least-squares regressions.200 The purpose of using PLS in multivariate 
calibration is to obtain a good insight and good predictive ability at the 
same time. 
Partial least-squares regression is a modelling procedure that 
simultaneously estimates the underlying factors in both the response matrix 
A and the concentration matrix C.195 The approach used by PLS is very 
similar to PCA, the difference being that factors are chosen to describe the 
variables in C as well as in A. This is done by using the columns of the C 
matrix to estimate the factors of A and at the same time, the columns of A 
are used to estimate the factors for C. The resulting models are 
summarized by 
A=UP+E (eq. 9) 
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and 
C=T Q+F (eq. 10) 
where the elements of U and T are called the scores of A and C, 
respectively, and the elements P and Q are called the loadings.195 The 
errors associated with modelling A and C with the PLS model are 
represented by the terms E and F. In PLS, the U factors are not optimal 
for estimating the columns of A as in PCA, but are rotated so as to 
simultaneously describe the C matrix. The factors for the A and C 
matrices have the following relationship 
T=BU+ e (eq. 11) 
where B is the inner relationship between the score matrix T and U. 
Partial least-squares regression will compromise the ability of the factors 
to describe the samples in the individual spaces to increase the correlation 
of U to T. It is this compromise that allows for the determination of a 
factor model that simultaneously describes A and C.195 
Two types of approach to PLS calibration have been developed 
depending on how many of the components of the C matrix are considered 
during calibration. When the calibration and prediction analysis are 
performed one component at a time, the method is called PLS1. Other 
concentrations, even if known, are not included in the analysis. Two or 
more components can be calibrated or analyzed simultaneously by using the 
PLS2 algorithm. zot 
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E. Data Analysis Used in the Study 
Since pure reference standard forms for the cholesterol lipid 
fractions are not available, neither are the absorbance spectra for the 
individual products of the color reaction. Except for possible competing 
color reactions with additives included with the samples to enhance the 
separation processes, the spectra for the fractions separated by 
ultracentrifugation or precipitation would be considered to be close 
approximations to reference spectra, Figure 3. Using the fact that the 
spectra obtained for reactions with standard reference material (SRM) 
forms of cholesterol and its esters are identical, we have presumed that the 
same molecular derivatives are produced in the color reaction with serum 
cholesterol, and that the spectral variations among the cholesterol fractions 
are due to the different cholesterol compositions and different matrix 
effects. Matrices in this case are the lipoprotein carriers used to transport 
cholesterol in serum. A model has to be developed, therefore, that will 
resolve the spectrum for the whole serum into the contributions from the 
different parts. 
In the original mathematical model, 186 absorbances A(i) were 
measured at three chosen wavelengths and lipid profiles were calculated by 
the simultaneous solution of a set of three equations of the form: 
A(i) = EVLDL-C(i)' [VLDL-C] ·b+ELDL-C(i)' [LD L-C] · b+EHDL-C(i) · [HDL-C] · b 
(eq.12) 
where b is the cell pathlength which is equal to 1-cm in all the 
measurements. Molar absorptivity coefficients e, were evaluated in a 
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totally empirical manner and were subject to investigator bias and over-
simplifications in the model. One over-simplification, that limited the range 
of TC over which the model could be applied, was that e values were 
presumed to be equal for all three of the lipid fractions at the wavelength 
of the major maximum (520 nm). There are zero degrees of freedom in 
this model, making it impossible to use it to predict the composition of 
every sample with equal precision. 
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(b) TC= 215 mg/dL 
(c) TC= 470 mg/dL 
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Figure 3. Absorption spectra for the reaction of cholesterol in (a) serum, 
and the individual fractions: (b) VLDL-C; (c) LDL-C; (d) HDL-C. 
To improve upon the mathematical model, more sophisticated multi-
variate calibration and prediction analyses were used. The multivariate 
calibration approach used was PLS2 which is a part of the spectroscopic 
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analysis software package available in UNSCRAMBLER II (CAMO A/S, 
Trondheim, Norway). Spectral resolution in the spectrophotometer is 2 nm 
so a full spectrum data set consists of 200 points, which represent an 
enormous increase in the number of degrees of freedom compared to the 
simpler analysis. 
As a basis for the multivariate calibration model, a training set was 
chosen that consisted of 35 samples in which there is a wide distribution in 
TC, as well as in the various lipid fractions in a conscious effort to 
approximate the ranges encountered in the entire population. The lipid 
profiles for these samples had been measured enzymatically at one or other 
of the external laboratories. As is usual, VLDL was taken to be 0.2xTG 
and numbers for LDL were calculated using the Friedewald formula. 
Ranges in values were as broad as we could access (Table 2) using the 
source laboratories. 
Background and weighting corrections were not applied. Other 
calibration parameters used are shown in Appendix A. The optimum fit to 
the· spectral data for the training set was obtained using four factors. The 
percent residual variance was about 25% with just the first factor, and less 
than 0.05% for all four. 
As a test to determine if analysis using the full spectrum data set was 
really necessary, the multivariate regression analysis subroutines were used 
to identify the optimum wavelengths, i.e. those that are most sensitive to 
variations of each fraction. Alternative models were tested using reduced 
data sets that were limited to 100, 30, 14, 6, and 4 wavelengths 
respectively. Differences in the percent residual variances were minimal 
from full spectrum through 6 wavelengths, and 4 wavelengths could be 
used with little loss in the quality of the fit. The primary model used in the 
work was based on 6 wavelengths. Measured absorbances for the samples 
in the training set are given in Table 3. 
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A justifiable criticism of the computational model is that calibration 
of the absorbance data to the lipid profiles of the training set is confined by 
the limitations set by the enzymatic method, namely that VLDL-C is taken 
to be 0.2xTG, and LDL-C is calculated from the Friedewald formula.21 
Four samples in the training set had values for TG >400 mg/dL, for which 
HDL-C values had been measured while VLDL-C and LDL-C values 
calculated. In spite of the risk that the Friedewald formula does not apply 
to the high TG levels, their inclusion in the training set is crucial so the 
mathematical model could approximate the entire population. The 6-
wavelength calibration model was used to predict lipid profiles for all the 
sera in the current sample pool. The color reaction was done on high 
triglyceride samples in precisely the same way, and it was assumed that the 
same model could be extrapolated to include them. 
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Table 2. Measured lipid profiles for the training set (mg/dL).a 
Sample VLDL-C VLDL-C LDL-C LDL-C HDL-C HDL-C TC TC 
Number (b) (c) (b) (c) (b) (c) (b) (c) 
1 27 31 128 157 73 53 229 241 
2 43 55 91 82 27 28 162 165 
3 44 40 187 161 31 55 263 256 
4 23 29 96 84 33 38 152 151 
5 20 23 110 94 30 46 161 163 
6 15 31 101 122 89 51 206 204 
7 12 30 132 116 51 41 196 187 
8 10 8 116 122 48 44 175 174 
9 11 14 121 147 75 52 212 213 
10 47 44 159 146 19 40 225 230 
11 6 5 127 135 55 49 189 189 
12 18 17 125 139 65 49 209 205 
13 9 5 92 88 39 44 141 137 
14 59 58 162 154 36 43 257 255 
15 8 10 145 137 49 53 203 200 
16 10 1 136 145 55 60 201 206 
17 52 64 221 218 55 57 329 339 
18 32 43 106 113 61 42 200 198 
19 40 28 173 176 42 60 256 264 
20 98 94 152 152 35 30 285 276 
21 82 73 147 161 33 37 262 271 
22 80 80 177 170 42 41 299 291 
23 87 62 87 115 34 39 208 216 
24 89 83 115 134 42 31 246 248 
25 32 37 132 156 66 44 230 237 
26 34 13 98 110 32 42 165 165 
27 51 47 222 200 39 60 313 307 
28 15 13 114 116 47 45 177 174 
29 22 23 111 97 31 34 165 154 
30 33 32 157 138 38 50 228 220 
Table 2. Continued 
Sample VLDL-C VLDL-C LDL-C LDL-C HDL-C HDL-C TC 
Number (b) (c) (b) (c) (b) (c) (b) 
31 27 47 207 170 42 50 277 
32 34 44 155 167 78 53 268 
33 24 23 184 170 49 57 258 
34 68 64 103 102 29 38 201 
35 35 22 122 123 35 42 192 
a The time interval between (b) and ( c) determinations was variable, 
sometimes as much as several days. 
(b) TC and HDL-C measured enzymatically, VLDL-C calculated as 
0.2x TG, and LDL-C calculated from the Friedewald equation. 
All measurements were made only once. 
( c) VLDL-C, LDL-C and HDL-C measured spectroscopically, TC 
calculated as the sum. Multiple independent measurements 
were made for all samples. 
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TC 
(c) 
267 
264 
250 
204 
187 
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Table 3. Absorbance dataa for the training set. 
Sample A362 A3ss A420 A4s6 As20 As46 
1 0.553 0.461 0.442 0.373 0.631 0.250 
2 0.459 0.369 0.332 0.271 0.414 0.164 
3 0.522 0.432 0.431 0.362 0.650 0.242 
4 0.330 0.273 0.251 0.204 0.337 0.126 
5 0.319 0.266 0.246 0.200 0.348 0.124 
6 0.378 0.312 0.305 0.253 0.467 0.164 
7 0.425 0.353 0.335 0.282 0.475 0.185 
8 0.349 0.302 0.303 0.255 0.446 0.176 
9 0.460 0.384 0.372 0.316 0.555 0.219 
10 0.484 0.395 OA03 0.343 0.623 0.233 
11 0.337 0.289 0.302 0.254 0.477 0.181 
12 0.432 0.362 0.353 0.300 0.529 0.206 
13 0.281 0.237 0.215 0.176 0.299 0.116 
14 0.568 0.461 0.460 0.387 0.681 0.257 
15 0.365 0.308 0.316 0.262 0.489 0.184 
16 0.421 0.358 0.335 0.288 0.507 0.199 
17 0.821 0.677 0.655 0.566 0.961 0.379 I 18 0.373 0.303 0.312 0.251 0.464 0.163 
19 0.472 0.389 0.411 0.346 0.671 0.243 
20 0.762 0.628 0.594 0.505 0.789 0.315 
21 0.581 0.463 0.480 0.407 0.747 0.273 
22 0.652 0.525 0.536 0.449 0.795 0.297 I 23 0.488 0.397 0.378 0.314 0.531 0.193 
24 0.580 0.468 0.463 0.391 0.670 0.247 
25 0.488 0.403 0.415 0.354 0.647 0.244 
26 0.351 0.296 0.285 0.238 0.410 0.161 
27 0.678 0.561 0.554 0.472 0.826 0.320 I 28 0.389 0.327 0.304 0.258 0.436 0.173 
29 0.365 0.300 0.282 0.236 0.396 0 1 "7 
30 0.471 0.390 0.377 0.316 0.550 0.210 
31 0.549 0.448 0.459 0.387 0.708 0.265 
32 0.538 0.451 0.461 0.384 0.680 0.257 I 33 0.455 0.376 0.401 0.334 0.642 0.238 
34 0.566 0.465 0.412 0.338 0.500 0.200 
35 0.403 0.338 0.331 0.280 0.486 0.189 
a Average absorbance from multiple measurements of each sample. 
CHAPTERV 
RESULTS AND DISCUSSION 
Rea,:ent Modification 
The original Chugaev reagent consisted of a 2:1 mixture of a 
solution of 20% ZnClz (w/v) in glacial acetic acid and 98% acetyl 
chloride.112 The experimental conditions called for incubation at 67°C for 
20 minutes. In an effort to find more convenient experimental conditions, 
various modifications to the reagent were tried. 
The first modification involved changing the relative composition of 
the reagent mixture. Zinc chloride was increased to 35% (w/v) and the 
acetyl chloride was increased to be in excess of the acetic acid by 100:1. 
These modifications increased the intensity of the absorbance signal but the 
reaction rate was not affected significantly. Incubation at 67°C was still 
required. The function of glacial acetic acid is as the solvent for the ZnC12 
but it appears to retard the reaction rate. In order to eliminate it, a variety 
of other salts were evaluated which were dissolved directly into acetyl 
chloride. Results are summarized in Table 4. The acetate and perchlorate 
salts of zinc had the best potential as substitutes for ZnClz. A number of 
solvents were also evaluated as alternatives to acetyl chloride. Among 
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these solvents were acetone, chloroform, acetic anhydride, methanol, and 
dichloromethane. When mixed with zinc perchlorate either the salt did not 
dissolve or no color was produced when incubated with cholesterol. 
Table 4. Metal salts evaluated as alternative to ZnCii. 
Salts Solubility in Color of the Gave color when 
acetyl chloride solution reacted with 
cholesterol 
Zn Cl~ not soluble - -
Zn(Cl04)2• 68z0 soluble colorless yes 
Zn(CH3C00)2 • soluble turned yellow after yes 
2Hz0 about 2 hours 
[CH3COCH=C(O)- soluble turned yellow -
CH3]2Zn· xH20 immediately 
Zn(SO 4)2° H20 soluble colorless no 
Zn(N03)z- 6H20 soluble turned yellow -
immediately 
ZnCO not soluble - -3 
CdC12 not soluble - -
AgN03 not soluble - -
Cd(Cl04)2° 68z0 not soluble - -
Ca(ClO 4)2° 6H20 not very soluble - -
Mg(Cl04)2 soluble colorless no 
Ba(Cl04)2° 3H20 not very soluble colorless yes but very small 
signal 
NaC104 not soluble - -
KC104 not soluble - -
65 
The properties of acetyl chloride were studied extensively by Paul 
and Sandhu. 202 They found that strongly ionic chlorides are insoluble in 
acetyl chloride and the development of color when substances are dissolved 
in acetyl chloride indicates the formation of complexes. Compounds that 
are capable of acting as Lewis acids are soluble. Acetyl chloride has a 
dielectric constant of 15.9 at 20°C, low compared to water, which may be a 
factor responsible for the insolubility of strongly ionic compounds. 
Solvation plays an important role in the dissolution of Lewis acids and 
bases in these non-aqueous media. 202 
With zinc perchlorate dissolved directly in acetyl chloride the rate of 
color production is much faster and .signal intensities much higher. One 
possible explanation is that the perchlorate ion is a stronger base compared 
to the acetate ion in abstracting hydrogen from the cholesterol molecule 
making the rate of color formation faster. A kinetic study of the reaction 
done in our laboratory showed that the reaction is 98% complete in 15 
minutes under room temperature conditions. The rate equation is first 
order in cholesterol and probably first order in zinc perchlorate but 
because the reagent is present in very large excess compared to cholesterol 
the order is reduced to pseudo-zero order. Taking the average cholesterol 
concentration to be 200 mg/dL, the mole ratio [Zn+2] : [cholesterol] is 
approximately 10,000: 1. 
Color and Spectra of Products 
Products of the reactions between the modified Chugaev reagent and 
standard reference material (SRM) forms of cholesterol and cholesterol 
esters dissolved in chloroform are pink in color. With serum, the color is a 
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fluorescent orange, the ultimate shade of orange being a function of the 
amount of serum cholesterol and its distribution among the lipoprotein 
fractions. Individual colors for the reactions with the subfractions, 
separated either by ultrafiltration (Sigma Chemical Co.), or by ultra-
centrifugation (Lipids Research Laboratory, Oklahoma Medical Research 
Foundation) are pink, orange, and yellow for VLDL-C, LDL-C, and 
HDL-C, respectively. Considering the lipoprotein particles as the local 
"solvents" for cholesterol in the concurrent reactions, the VLDL-C 
particles, having the highest proportion of TG and the lowest protein, are 
the least polar of the lipoproteins and would behave most like chloroform 
in the test with cholesterol. Colors for the VLDL-C and the SRM of 
cholesterol are the most alike. The spectral shift from pink to yellow in 
going from VLDL-C through LDL-C to HDL-C, parallels the relative 
increase in polarity. Absorbance spectra for the SRM of cholesterol and its 
esters cannot be used to calibrate the analyses of serum cholesterol because 
of the environmental effects of the lipoprotein matrices on the electronic 
absorbance spectra for cholesterol in the various sub-fractions (Figure 3). 
In contrast, the Liebermann-Burchard reagent, reacted with the lipoprotein 
subfractions, gives the same spectrum for all three fractions. It cannot, 
therefore, be used for the discrimination of the lipoprotein fractions. 
Absorption spectra for the colored products from the reactions of 
three serum samples with different TC levels are shown in Figure 4. The 
absorbances at "'max (520 nm) do not obey Beer's Law and the overall 
shape of the spectra depends upon the distribution of cholesterol among the 
lipid fractions. In Figure 5, on the other hand, absorption spectra are 
compared for the colored products of the reactions of cholesterol in three 
different serum samples which had the same TC but different lipid profiles. 
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Figure 4. Absorption spectra for the colored product of the reaction of 
cholesterol with three serum samples with different TC. 
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Figure 5. Absorption spectra for the colored product of the reaction with 
three serum samples with the same TC but different TG levels. 
68 
All three have similar absorbance at the 520 run maximum, representative 
of the fact that they have the same TC values, 180 mg/dL, as measured 
enzymatically. This part of the spectrum is dominated by the LDL-C 
fraction, Figure 3, which, from population averages accounts for as much 
as 65% of the total serum cholesterol. 52 The critical part of the spectrum 
for discrimination among LDL-C and other lipid fractions is clearly in the 
range 360-480 run. More specifically, absorbances in the 360-430 range 
are seen to increase as TG increases, Figure 5. The increase in absorbance 
in the 362 run absorbance maximum, however, does not correlate linearly 
with the increase in TG. A linear dependence would only occur if the band 
was due exclusively to the absorption by VLDL-C, and the approximation 
was true that VLDL-C = 0.2 x TG at all levels of TG, which it is not. The 
transition with increasing TG, however is monotonic and smooth which 
might imply that the mathematical model used to analyze the spectral data 
will, in fact, be applicable to samples with high TG levels. 
Calibration 
Since pure forms of the cholesterol lipid fractions are not available, 
neither are the spectra for the individual products of the color reaction. 
Therefore, a mathematical model has to be developed that will resolve the 
whole spectrum into the contribution from the parts. 
(a) 3x3 Matrix Solution: In the original work, 186 absorbances Ai , were 
measured at three chosen wavelength and the lipid profiles were calculated 
by solving a set of three simultaneous equations of the form: 
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A(i)=EvLDL-C(i). [VLDL-C]. b + Er.oL-C(i). [LD L-C] ·b+EiJoL-C(i). [HD L-C] ·b 
(eq. 12) 
where b is the sample pathlength. The nine E coefficients were evaluated in 
a totally empirical manner and are subject to investigator bias and over-
simplification in the model. The model is also seriously limited by having 
zero degrees of freedom in the data. Using this method of data analysis, 
good correlation between methods was obtained only for LDL-C and TC. 
(b) Multivariate Regression Analysis (MVRA): Lipid profile and 
TC results for the work reported here were determined using MVRA 
techniques. The use of six data points increased the degrees of freedom. 
The training set: 
The mathematical model that describes the relationship between 
absorbance and the concentration of the three major lipoprotein fractions 
was established by creating a training set or calibration set. The training set 
consisted of samples that were chosen to have as wide a distribution of TC 
as well as all the lipid fractions as possible such that it would approximate 
the distributions in the entire population. This would make the 
mathematical model predict better the concentration of future samples. 
In this study, thirty five samples were chosen for the training set. 
They included 21 samples from UWC and 4 high TG samples from RBL. 
Lipid profiles used in the calibration had been measured enzymatically, 
VLDL-C was taken to be 0.2 x TG, and the numbers for LDL-C were 
calculated using the Friedewald formula. Ranges in the values of the lipid 
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fractions were as wide as we could access (Table 2). Using the linear PLS2 
algorithm, with six absorbance measurements for each sample, the 
following calibration equations were obtained 
[VLDL-C] = 870.4·A362 - 1702.0·A388 + 415.5·A420 + 1779.0·A456 - 145.81·A520 
- 1682.0-A546 (eq. 13) 
[LDL-C] = -786.5·A362 + 1569.0·A388 -17.9·A420- 1846.0·A456 +594.6·A520 
+ 758.0-A546 (eq. 14) 
[HDL-C] = -690.5-A362 + 1659.0-A388 + 6.0·A420 -1935.0·A456 + 509.4·A520 
+ 271.8-A546 (eq. 15) 
and were used to predict the concentrations of the fractions in all of the 
samples in the training set as well as future samples. Lipid profiles for the 
members of the training set, predicted using the multivariate analysis, are 
compared with the results from the independent sources in Table 2. 
Between-methods correlation plots and correlation equations for TC 
and the various fractions of the samples that form the training set are 
shown in Figures 6 and 7. They-intercepts are all positive, a result that can 
be expected when comparing between methods that have quite different 
experimental uncertainties. The TC correlation is excellent. Because TC is 
measured by the enzymatic method, but calculated in the spectroscopic 
method from the sum of the fractions, the validity of the multivariate 
method is substantiated. Correlations are also very good for VLDL-C and 
LDL-C. The poorest correlation is seen for HDL-C, but there is a 
significant improvement over the results from earlier work.187 Results 
from paired Student's t-test of the training set showed that correlations 
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Figure 6. Correlation plots between methods for TC (upper) and VLDL-C 
(lower) for the training set. Concentrations are in mg/dL. 
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Figure 7. Correlation plots between methods for LDL-C (upper) and 
HDL-C (lower) for the training set. Concentrations are in mg/dL. 
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between the enzymatic and the spectroscopic methods do exist, Table 5. 
Table 5. Paired student's t-test of samples used in the training set analyzed 
by the enzymatic and the alternative methods. 
(N=35) 
Fraction 
VLDL-C 
LDL-C 
HDL-C 
TC 
at ex. = 0.05; 
df= 34 
Prediction 
Mean 
difference 
0.11 
-0.17 
0.20 
0.94 
ttable = + 2.042 
SD difference texn 
9.80 0.066 
16.23 -0.062 
14.48 0.082 
6.21 0.896 
Calibration equations (eq. 13-15) obtained from data for the training 
set were subsequently used to predict the concentrations of all the other 
samples tested. There were several sources of the serum samples as 
described earlier. The results are discussed independently then collectively 
in the following sub-sections. 
I. OSU Wellness Center (UWC) 
The most extensive comparison was made with samples obtained 
from the UWC (n=304). Some samples were only analyzed by our 
laboratory, so comparisons are incomplete. Individual results are shown in 
Appendix B-1. For samples with TG < 400 mg/dL, the VLDL-C fraction 
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was calculated as TG/5 and LDL-C by the Friedewald formula. For 
samples with TG > 400 mg/dL, precipitation of HDL-C is usually not done 
so only TG and TC would be reported by the other laboratory. For some 
samples, HDL-C values were reported even when TG > 400 mg/dL. The 
VLDL-C and LDL-C fractions for these samples were estimated using the 
Friedewald formula although the limit of the formula is exceeded. Very 
good correlations were obtained for both TC and LDL-C, Figures 8 and 9. 
The correlation coefficient is much smaller for VLDL-C which can be 
attributed in part to the empirical way that VLDL-C is calculated in the 
enzymatic method and the fact that for some samples the upper TG limit 
was exceeded. The current model indicates that there is no correlation for 
HDL-C. It is difficult to apportion the relative errors between methods but 
since VLDL-C and LDL-C are obtained empirically in the enzymatic 
method, and high TG samples are included in the training set, some of the 
error is associated with the reference method. Until these have been 
reduced, the errors in measuring HDL-C by the alternative method cannot 
be evaluated. The differences between methods appear to be greatest when 
HDL-C levels are high, > 60 mg/dL, suggesting the absorbance may change 
non-linearly for this fraction. The only way to resolve the problem is to 
use ultracentrifugation data as the reference method. 
II. Roche Medical Laboratories and Stillwater Medical Center 
Samples from these two laboratories were exclusively high TG 
(>250 mg/dL). These samples were of interest because they represent a 
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Figure 8. Correlation plots between methods for TC (upper) and VLDL-C 
(lower) for the OSU Wellness Center samples. Concentrations are in 
mg/dL. 
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Figure 9. Correlation plots between methods for LDL-C (upper) and 
HDL-C (lower) for the OSU Wellness Center samples. Concentrations are 
in mg/dL. 
population with any of a number of lipid disorders. Having a routine 
method for measuring their lipid fractions would be helpful in the early 
detection and management of the disorders. Current routine methods fail 
for these samples. Ultracentrifugation is the only way to obtain the 
information. 
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Absorbances in the 360-430 nm range increase dramatically with 
increasing TG (Figure 5). The increase in the maximum absorbance at 362 
nm is non-linear with the amount of TG. 
Comparisons of the lipid profiles of samples from RBL (n=53) and 
SMC (n=251) obtained with the enzymatic method and the alternative 
method are shown in Appendices B-II and III. Correlation plots of TC 
between the enzymatic and the alternative methods for these samples are 
shown in Figure 10. The correlations are very good. The VLDL-C 
obtained by MVRA is generally smaller in comparison to the value 
obtained by TG/5 for high TG samples. This is consistent to the limitations 
set by the Friedewald formula. Comparisons between methods for the lipid 
fractions for the majority of these high TG samples cannot be made. 
However, HDL-C of some of these high TG samples were reported by the 
other laboratories (n=21 for RBL and n=4 for SMC) and the values 
obtained by MVRA were comparable to those obtained for UWC. The 
LDL-C for these samples obtained by MVRA are greater than those 
approximated from the Friedewald formula. One possible explanation for 
the higher LDL-C values is that VLDL-C is underestimated making the 
LDL-C higher. The obvious failure of the calibration model to predict the 
lipid profiles of these abnormal samples, even when TC values correlate, 
suggests that there is an essential factor missing from the model which 
would redistribute the cholesterol over the fractions. 
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y = 2.21 + 1.06x R= 0.971 
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Figure 10. Correlation plots between methods for TC of samples from 
Roche Biomedical Laboratory(upper) and Stillwater Medical Center 
(lower). Concentrations are in mg/dL. 
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III. University of Cape Town Medical School (UCT) 
The UCT lipids laboratory is involved with research into lipid 
dysfunctionalities, particularly Type III lipid disorder and familial 
hypercholesterolemia (FH). Individuals with FH have significantly high 
LDL-C levels and are at a very high risk for atherosclerosis. In Type III 
lipid disorders, the level of IDL-C is increased indicating a defect in the 
metabolism of the lipoproteins. Detection and management of these 
disorders requires ultracentrifugation which is both labor and financially 
intensive. Our collaboration is to evaluate the spectrophotometric method 
as a potential alternative. Samples from UCT were separated using the 
preparative ultracentrifuge and lipid profiles obtained by this method can 
also provide a check on the validity of the current model which is based on 
the routine enzymatic method. 
There are no obvious differences in the spectra for reactions with the 
plasma of normal, Type III, and FH individuals. Comparison of the lipid 
profiles of samples from UCT are shown in the Appendix B-IV. 
Considering the possible effects of lipid dysfunctionalities on both the 
separation and photometric technologies, correlation plots between the 
methods are very good for TC and LDL-C for both normal and Type III 
samples, Figure 11. Once again, the HDL-C correlation is not good (Figure 
12). For VLDL-C, there is a good correlation between the two methods if 
comparing normal samples (Figure 13). The current model is predicting 
the VLDL-C concentration lower than the one obtained by ultra-
centrifugation method for Type III individuals (Figure 13 ), as it did for 
high TG samples in the RBL subset. 
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Figure 11. Correlation plots between methods for TC (upper) and LDL-C 
(lower) for all the samples from the University of Cape Town. 
Concentrations are in mg/dL. 
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Figure 12. Correlation plot between methods for 
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HDL-C for all the samples from University of Cape Town. Concentrations 
are in mg/dL. 
A significant factor in lipid dysfunctionalities that is not measured in 
the routine enzymatic screening is the IDL-C fraction. This fraction is 
described to be VLDL-C like in structure but with a cholesterol loading 
similar to LDL-C. The IDL-C levels are high in Type III and low in 
normal and FH cases. A calibration model that includes the IDL-C fraction 
would be desirable to evaluate the abnormal samples and would probably 
help improve the correlations among the other lipid fractions particularly 
HDL-C. An obvious difference can be seen on the spectra of type III and 
FH or normal individual (Figure14) using the first fraction (fraction A) 
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Figure 13. Correlation plots between methods for VLDL-C for the 
University of Cape Town samples with no lipid disorder (upper) and with 
known Type ill lipid disorder (lower). Concentrations are in mg/dL. 
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Figure 14. Absorbance spectra of fraction A (obtained by 
ultracentrifugation) of individuals that are normal or with Type III and FH 
lipid disorder. 
after ultracentrifugation. It is hard to distinguish between the spectra of FH 
and normal individuals (Figure 15). The A fraction was obtained using a 
density=l.006 g/mL cushion to float the A layer which is mostly VLDL-C. 
The spectra of fraction A of Type III individuals show a large absorbance 
at 520 nm compared to the absorbance at 362 nm. The spectra for fraction 
A for FH and normal individuals are similar to each other having a very 
low intensity and the absorbance at 362 nm is greater than the absorbance 
at 520 nm. More samples having a confirmed Type III and FH conditions 
need to be analyzed to check if the spectra of the A fraction really 
correlates with a lipid disorder. 
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Figure 15. Absorbance spectra of fraction A (obtained by 
ultracentrifugation) of individuals that are normal and with FH lipid 
disorder. 
Combined data from the four laboratories 
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Some statistics on the raw data of the combined results from the four 
different laboratories are shown in Table 6. The result of the Student's t-
test comparing the alternative method and the method used by the external 
laboratories are shown in Table 7 while the correlation coefficients are 
shown in Table 8. 
The correlation coefficients in Table 8 show that a linear correlation 
exists between the alternative method and the method used by the external 
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Table 6. Statistics on the lipid profiles obtained by two methods of the 
samples from the four laboratories. 
Statistic VLDL-C LDL-C 
(a) (b) (a) (b) 
minimum 6 -8 39 42 
maximum 98 107 250 246 
number 469 469 327 327 
of points 
mean 43 37 146 147 
.~ .. , 
median 35 35 145 146 
population 
standard 24.3 21.8 39.0 32.0 
deviation(SD) 
(a) Method used by external laboratories. 
(b) Alternative method using MYRA. 
HDL-C TC 
(a) (b) (a) (b) 
19 1 58 63 
89 74 439 439 
327 327 611 611 
43 43 228 231 
41 43 226 228 
13.0 11.1 53.6 56.2 
Table 7. Results of Student's t-test using all the data from the four external 
laboratories. 
Statistic VLDL-C LDL-C HDL-C TC 
minimum difference -37 -70 -32 -57 
maximum difference 81 49 44 31 
number of points 469 327 327 611 
mean difference 5.5 -0.86 -0.05 -3.5 
S.D difference 15.7 17.8 14.7 14.0 
texp ( calculated) 7.59 -0.87 -0.06 6.18 
t .ti al at ex= 0.05 enc 1.96 1.96 1.96 1.96 
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Table 8. Correlation coefficients (r). 
Alternative method VLDL-C vs. External laboratories VLDL-C (n=469) 0.770 
Alternative method LDL-C vs. External laboratories LDL-C (n=327) 0.893 
Alternative method HDL-C vs. External laboratories HDL-C (n=327) 0.285 
Alternative method TC vs. External laboratories TC (n=611) 0.969 
Critical value of r (a.= 0.05) = 0.195 
laboratories. The weakest of the correlations is for HDL-C. The model is 
unable to predict high concentrations of HDL-C suggesting that the 
response might not be linear at high HDL-C concentrations. Also, it would 
appear that a model that is based on ultracentrifugation or beta-
quantification of the lipoprotein fractions with the IDL-C fraction 
accounted for would be desirable for proper calibration and prediction. 
Although a correlation exists between the two methods on TC and the lipid 
fractions, results of the t-test show a significant difference in TC and 
VLDL-C. This is posible if there were a constant determinate error in one 
method making the differences significant even though a good correlation 
between the methods exist. The estimation of VLDL-C by TG/5 may be a 
source of error contributing to the significant difference in VLDL-C 
between these two methods which subsequently affect the TC. Another 
source of the discrepancy might relate to the fact that in the alternative 
method the test is done in duplicate but in the external laboratories tests are 
done only once. 
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Precision Studies 
To assess the precision of the alternative method, analyses were done 
several times for one serum. Three serum samples were chosen that have 
different values of their total cholesterol. Table 9 summarizes the results of 
the precision studies while the lipid profiles obtained for each analysis is 
Table 9. Results of the precision studies. 
' 
VLDL-C LDL-C HDL-C TC 
(mg/dL) (mg/dL) (mg/dL) (mg/dL) 
Sample 1 
(a) Enzymatic 32 159 42 234 
(b) Spectroscopic 25 165 47 238 
n=lO 
SD 2.6 4.1 1.9 3.1 
%CV 10.2 2.5 4.0 1.3 
Sample 2 
(a) Enzymatic 7 47 37 89 
(b) Spectroscopic 19 49 23 91 
n=6 
SD 3.4 3.2 1.9 1.9 
%CV 17.9 6.7 8.0 2.0 
Sample 3 
(a) Enzymatic 20 104 33 157 
(b) Spectroscopic 8 107 40 155 
n=lO 
SD 4.5 4.1 1.4 3.1 
%CV 58.4 3.8 3.5 2.0 
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shown in Appendix C. Since outside laboratories make one measurement 
for each serum, comparisons of the precisions cannot be made. 
Results obtained from the precision studies showed that the 
alternative method passes the requirements set by LSP for TC. The 
requirement of the LSP for CV of~ 3% for LDL-C and~ 4% for HDL-C 
is not completely fulfilled particularly at low levels of this lipid fractions. 
Interference Studies 
To test the effects of other endogenous substances on the alternative 
method, weighed amount of various solid substances were added to 1 ml 
aliquots taken from two pooled samples prepared by mixing serum from 
nine individuals. Spectra and data were analyzed the usual way. Results are 
shown in Table 10. Initial amounts added to the serum ( column 4) were 
equal to the highest test levels encountered in practice. It should be 
understood that these amounts are in excess of the "normal" high values 
(column 2). 
Table 10. Results of the interference studies. 
Compound High High test Amount VLDL-C LDL-C HDL-C TC 
added "normal" levels added (mg/dL) (mg/dL) (mg/dL) (mg 
concen- (mg/dL) to serum /dL) 
tration (mg/dL) 
(mg/dL) 
serum 1 - - - 18 110 46 174 
urea 38 500 500 16 109 42 167 
creatinine 1.5 30 30 15 108 44 166 
fructose 7.5 30 30 18 108 43 169 
citrate 3.0 30 30 21 103 40 164 
d-glucose 110 1200 1200 22 107 39 168 
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Table 10 ( continued). Results of the interference studies. 
Compound High High test Amount VLDL-C LDL-C HDL-C TC 
added "normal" levels added (mg/dL) (mg/dL) (mg/dL) (mg 
concen- (mg/dL) to serum /dL) 
tration (mg/dL) 
(mg/dL) 
serum 1 - - - 18 110 46 174 
hemoglobin 2.5 500 500 34 118 53 205 
250 36 92 33 161 
125 34 90 42 167 
62,5 32 94 44 170 
31.25 24 105 48 177 
serum2 - - - 22 98 40 160 
albumin 5000 6000 6000 32 85 33 150 
3000 29 86 34 149 
1500 24 94 37 155 
750 18 100 40 158 
"t-J?:lobulin 5000 6000 6000 21 94 38 153 
3000 29 85 35 149 
1500 29 85 35 149 
750 28 97 38 163 
Results of the interference studies showed that only hemoglobin, 
albumin and globulin have an effect on the measurement if they are present 
in very high concentrations. Quantities of the interferences were 
progressively decreased to determine the treshold level for the 
interference. These levels are also shown in Table 10. The interference that 
is of primary concern is hemoglobin because very often in the collection of 
venous blood some rupture of the red cells will occur. The interference 
treshold is 15 times greater than the "normal" high serum value. 
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Linearity Tests 
A linear Beer's Law dependence for TC is observed when the SRM 
of cholesterol is dissolved in chloroform, an isotropic solvent. Correlation 
tests made by spiking serum with SRM were non-linear because of 
changing matrix effects. A test was made by mixing two serums which had 
different TC and different lipoprotein levels in varying proportions and 
analyzing the spectra the usual way. Results are given in Table 11 and 
correlation plots are shown in Figure 16. 
Table 11. Results of the linearity tests. 
Serum 1 Serum 2 VLDL-C LDL-C HDL-C TC 
100% 
-
21 93 37 151 
75% 25% 17 109 38 164 
50% 50% 22 131 40 193 
25% 75% 20 151 48 219 
- 100% 13 165 50 228 
Results of the linearity tests showed that the alternative method is 
sensitive to the increase in concentration in LDL-C, HDL-C and TC. The 
response was linear over the concentration ranges that were studied. The 
limits to the ranges need to be evaluated in further work. The majority of 
the normo-lipid serum measured by the external laboratories are covered 
by the ranges expressed for TC, LDL-C, and HDL-C in Table 11, which 
further substantites the linearity correlations between methods for LDL-C 
and TC, Figures 8-11. 
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Figure 16. Plots of the concentration of the lipoprotein obtained by the 
alternative method against fraction of Serum 2 added to Serum 1: 
(A) VLDL-C, (B) LDL-C, (C) HDL-C, and (D) TC. 
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
The most significant result that has emerged from this study is that, 
the amount of cholesterol in the major lipoprotein fractions has been 
measured routinely and directly without resorting to any fractionation 
step(s). The good correlation between TC values, measured by distinctly 
different procedures, validates both the physical interpretation of the 
spectrum for whole serum, and the mathematical model that is used to fit 
the data. Correlations between the alternative method and current routine 
methods for all the fractions and TC were better than reported in previous 
d. 26-27,t86Al h . 1 d'. h . 1 h stu 1es. so, t e expenmenta con 1tlons are muc srmp er t an 
the previous studies using a one-reagent system with the reaction occurring 
at room temperature. The precision of the alternative method for TC is 
very good and passes the requirement of the Laboratory Standardization 
Panel. 
In the process a method has been developed for the direct 
determination of LDL-C which is independent of empirical approximations 
such as the Friedewald equation. Reducing the number of steps needed for 
profiling from three to one, and eliminating an intermediate selective 
precipitation that separates low from high density fractions, should have 
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the effect of improving upon the overall accuracy in the measurements for 
all fractions. 
A third advantage offered by the alternative method is that lipid 
distributions for high TG samples can be measured. These data might now 
be considered in assigning risk factors for CHD. Quite often the evidence 
for failure of the Friedewald approximation in high TG samples are 
negative values for LDL-C and HDL-C. This will happen because VLDL-C 
is larger than 0.2xTG in these cases. 
Preliminary studies have shown that a spectral difference can be seen 
in the A fraction of Type III individuals. More samples with confirmed 
lipid disorders need to be tested to see if the alternative method can provide 
an easy way to detect the various lipid disorders. 
One critique of the method is that it is based on a lipid profile 
provided by a certified test laboratory but not a primary resource 
laboratory. The next development step is to prepare a training set using 
lipid profile data that were obtained using primary reference methods 
developed and recommended by the Center for Disease Control such as 
ultracentrifugation data. A training set based on ultracentrifugation which 
also includes the IDL-C fraction in the training set is the recommended 
next step. With these as the basis, there should be a significant 
improvement in the correlation and slope for all the lipid fractions. 
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Appendix A 
Calibration Parameters Used 
Model Center: Origin 
Default weights: 1/ Standard Deviation 
Outlier Detections: On Limit: 3.0 
Leverage Detection: On Limit: 0.9 
Calibration Method: Partial Least Squares 2 
Validation Method: Cross Validation 
Add Start Noise?: Yes 
Segment Selection: Random 
Number of Segments: 35 
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AppendixB 
Raw Data 
I. Lipid profiles of samples from OSU Wellness Center. 
Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
... , . .,~ 
1 280 56 58 101 108 28 42 185 208 
2 55 11 39 133 140 62 64 206 243 
3 130 26 19 143 161 50 58 219 238 
4 95 19 11 129 134 38 42 186 187 
5 354 70 55 182 189 28 49 280 293 
6 70 14 24 97 109 57 29 168 162 
7 140 28 28 69 88 50 24 147 140 
8 150 30 25 223 214 38 63 291 302 
9 110 22 5 130 140 35 48 187 193 
10 60 12 2 147 153 42 52 201 207 
11 105 21 3 173 186 40 67 234 256 
12 65 13 3 90 109 43 39 146 151 
13 135 27 12 196 182 26 54 249 248 
14 120 24 30 120 108 37 28 181 166 
15 275 55 33 86 115 29 34 170 182 
16 552 105 118 8 234 231 
17 215 43 19 177 175 40 55 260 249 
18 195 39 39 118 112 31 29 188 180 
19 40 8 23 85 76 39 23 132 122 
20 280 56 44 141 143 38 40 235 227 
21 250 50 33 148 152 41 41 239 226 
22 115 23 18 248 240 51 69 322 327 
21 85 17 21 73 74 49 26 139 121 
109 
110 
Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
24 165 33 26 217 201 50 58 300 285 
25 160 32 36 132 157 66 45 230 238 
26 50 10 8 117 122 48 43 175 173 
27 440 91 133 18 241 242 
28 55 11 14 126 146 75 52 212 212 
29 1710 276 41 -61 236 256 
30 524 113 133 14 253 260 
31 235 47 43 159 146 19 40 225 229 
32 30 6 4 128 135 55 49 189 188 
33 170 34 12 99 109 32 42 165 163 
34 85 17 23 177 152 43 49 237 224 
35 135 27 31 129 156 73 53 229 240 
36 255 51 46 223 199 39 60 313 305 
37 215 43 55 92 82 27 28 162 165 
38 105 21 15 137 134 39 52 197 201 
39 75 15 12 115 116 47 45 177 173 
40 250 50 55 123 111 25 35 198 201 
41 60 12 29 133 115 51 40 196 184 
42 175 35 22 122 123 35 41 192 186 
43 110 22 22 112 97 31 35 165 154 
44 135 27 30 182 168 34 53 243 251 
45 90 18 16 126 139 65 49 209 204 
46 295 59 57 162 154 36 43 257 254 
47 45 9 4 93 87 39 43 141 134 
48 165 33 31 157 137 38 49 228 217 
49 40 8 9 146 137 49 52 203 198 
50 135 27 45 208 170 42 50 277 265 
51 205 41 35 173 163 36 55 250 253 
52 165 33 24 152 150 46 54 231 228 
53 65 13 6 133 146 71 62 217 214 
54 488 98 94 152 151 35 29 285 274 
55 50 10 0 136 145 55 60 201 205 
56 260 52 63 222 219 55 57 329 339 
57 115 23 13 189 173 41 58 253 244 
58 65 13 18 135 139 56 46 204 203 
111 
Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
59 125 25 31 166 165 58 51 249 247 
60 305 61 55 127 139 41 33 229 227 
61 135 27 36 160 136 37 43 224 215 
62 170 34 30 191 175 32 54 257 259 
63 115 23 22 204 200 45 62 272 284 
64 210 42 53 160 166 38 53 240 272 
65 170 34 43 156 166 78 52 268 261 
66 130 26 29 113 109 37 46 176 184 
67 75 15 15 131 130 42 48 188 193 
68 95 19 22 153. 144 46 51 218 217 
69 22 116 43 181 
70 160 32 43 107 112 61 41 200 196 
71 160 32 34 220 199 41 64 293 297 
72 120 24 22 185 170 49 57 258 249 
73 100 20 12 155 146 47 58 222 216 
74 200 40 38 163 158 48 49 251 245 
75 325 65 64 122 152 66 47 253 263 
76 130 26 15 165 154 34 58 225 227 
77 200 40 28 174 176 42 60 256 264 
78 185 37 29 135 125 45 57 217 211 
79 2995 243 77 -23 263 297 
80 120 28 35 153 123 45 40 226 198 
81 220 44 40 188 161 31 55 263 256 
82 115 23 28 96 83 33 37 152 148 
83 115 23 21 187 164 46 60 256 245 
84 100 20 23 111 93 30 46 161 162 
85 75 15 30 102 121 89 51 206 202 
86 22 142 52 216 
87 465 97 118 25 246 240 
88 340 68 64 104 102 29 38 201 204 
89 75 15 8 134 137 54 55 203 200 
90 80 16 14 211 174 45 62 272 250 
91 155 31 37 178 144 26 40 235 221 
92 155 31 35 203 173 36 49 270 257 
93 90 18 24 118 103 35 30 171 157 
112 
Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
94 75 15 35 183 158 58 50 256 243 
95 75 15 24 144 143 64 49 223 216 
96 50 10 23 103 91 43 39 156 153 
97 85 17 18 179 155 42 54 238 227 
98 160 32 33 184 160 36 43 252 236 
99 205 41 32 156 156 36 42 233 230 
100 205 41 24 166 172 54 50 261 246 
101 115 23 30 138 120 33 35 194 185 
102 150 30 25 193 166 37 44 260 235 
103 75 15 20 116 114 45 37 176 171 
104 135 27 31 148 147 50 37 225 215 
105 215 43 63 167 172 65 37 275 272 
106 50 10 13 145 144 47 48 202 205 
107 476 86 201 34 329 321 
108 80 16 29 154 163 80 49 250 241 
109 95 19 27 127 136 62 41 208 204 
110 315 63 62 117 109 28 28 208 199 
111 90 18 21 190 170 48 47 256 238 
112 55 11 24 112 103 57 40 180 167 
113 55 11 15 138 144 66 50 215 209 
114 80 16 34 162 143 42 49 220 226 
115 140 28 31 240 201 36 64 304 296 
116 160 32 34 111 104 27 40 170 178 
117 60 12 26 89 98 64 41 165 165 
118 125 25 37 167 157 49 48 241 242 
119 180 36 48 178 152 35 48 249 248 
120 110 22 38 180 160 52 52 254 250 
121 65 13 31 153 128 43 50 209 209 
122 45 9 25 140 128 57 41 206 194 
123 100 20 31 141 131 40 41 201 203 
124 150 30 35 160 150 47 42 237 227 
125 130 26 28 169 152 41 49 236 229 
126 315 63 57 164 151 30 41 257 249 
127 110 22 39 126 134 70 38 218 211 
128 115 23 35 143 124 27 41 193 200 
113 
Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
129 215 43 53 135 127 30 34 208 214 
130 45 9 9 154 144 53 45 216 198 
131 85 17 14 143 121 29 43 189 178 
132 95 19 20 158 134 41 45 218 199 
133 195 39 33 251 201 23 51 313 285 
134 125 25 37 210 179 55 49 290 265 
135 190 38 39 175 161 34 44 247 244 
136 95 19 24 179 157 43 41 241 222 
137 80 16 28 163 140 51 44 230 212 
138 105 21 14 121 142 68 35 210 191 
139 155 31 27 183 170 37 43 251 240 
140 160 32 29 184 163 30 44 246 236 
141 205 41 55 154 143 42 29 237 227 
142 125 25 35 181 166 50 45 256 246 
143 70 14 14 130 124 40 41 . 184 179 
144 145 29 36 168 139 29 37 226 212 
145 165 33 52 172 145 49 33 254 230 
146 235 47 41 166 164 38 44 251 249 
147 120 24 35 151 153 60 42 235 230 
148 240 48 52 157 150 42 34 247 236 
149 110 22 28 117 112 40 36 179 176 
150 85 17 44 150 147 56 41 223 232 
151 155 31 25 133 156 37 47 201 228 
152 100 20 8 122 145 43 47 185 200 
153 135 27 54 126 125 58 24 211 203 
154 330 66 68 163 177 39 33 268 278 
155 240 48 54 140 131 22 29 210 214 
156 100 20 44 162 161 65 36 247 241 
157 130 26 44 178 169 54 40 258 253 
158 120 24 19 123 116 31 28 178 163 
159 165 33 27 189 179 45 46 267 252 
160 402 80 71 104 133 28 23 212 227 
161 90 18 26 116 112 55 37 189 175 
162 70 14 18 75 68 29 26 118 112 
163 180 36 41 150 137 29 37 215 215 
114 
Sam- TG VLDL- VLD LDL- LDL- HDL- HDL- TC TC 
pie C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
164 170 34 39 108 98 26 28 168 165 
165 170 34 45 166 161 43 38 243 244 
166 140 28 38 190 173 39 46 257 257 
167 150 30 44 174 155 35 38 239 237 
168 969 135 89 -8 214 216 
169 65 13 26 176 158 54 46 243 230 
170 80 16 34 162 157 56 39 234 230 
171 185 37 57 149 130 33 30 219 217 
172 155 31 50 152 146 46 34 229 230 
173 55 11 10 130 119 40 36 181 165 
174 115 23 38 196 181 32 31 251 250 
175 265 53 39 132 142 28 22 213 203 
176 230 46 65 233 215 51 38 330 318 
177 175 35 43 196 176 32 35 263 254 
178 85 17 27 247 212 43 69 307 308 
179 185 37 33 101 88 26 43 164 164 
180 130 26 43 200 193 52 56 278 292 
181 415 83 77 152 164 25 33 260 274 
182 350 70 107 154 145 31 21 255 273 
183 170 34 52 125 110 44 38 203 200 
184 1146 183 126 -15 309 294 
185 150 30 26 194 195 33 51 257 272 
186 45 9 16 90 111 63 38 162 165 
187 115 23 49 134 142 69 32 226 223 
188 135 27 35 147 146 40 39 214 220 
189 521 97 155 16 241 268 
190 80 16 10 183 196 48 60 247 266 
191 120 24 33 121 144 59 41 204 218 
192 125 25 32 183 178 41 46 249 256 
193 145 29 45 205 208 54 47 288 300 
194 100 20 24 197 195 35 58 252 277 
195 90 18 25 139 152 45 49 202 226 
196 350 70 70 128 134 32 30 230 234 
197 140 28 35 177 181 35 49 240 265 
198 105 21 29 198 184 31 52 250 265 
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Sam- TG VLDL- VLD LDL- LDL- HDL- HDL- TC TC 
pie C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
199 85 17 23 191 190 43 53 251 266 
200 145 29 34 211 214 44 55 284 303 
201 700 133 176 11 283 320 
202 55 11 15 162 166 46 55 219 236 
203 135 27 43 117 123 45 36 189 202 
204 43 138 37 218 
205 305 61 81 130 147 29 37 220 265 
206 442 88 73 218 246 32 52 338 371 
207 170 34 62 240 225 42 56 316 343 
208 155 31 40 156 139 26 39 213 218 
209 60 12 18 114 114 42 38 168 170 
210 70 14 27 100 100 47 33 161 160 
211 165 33 49 138 171 85 41 256 261 
212 95 19 18 114 125 44 40 177 183 
213 330 66 62 99 119 27 25 192 206 
214 155 31 40 217 201 37 57 285 298 
215 100 20 20 114 132 58 41 192 193 
216 65 13 9 160 169 54 50 227 228 
217 395 79 89 226 214 29 36 334 339 
218 120 24 26 140 157 54 56 218 239 
219 70 14 17 123 129 48 46 185 192 
220 105 21 33 106 121 56 38 183 192 
221 65 13 28 142 151 68 48 223 227 
222 85 17 13 136 134 41 51 194 198 
223 155 31 30 152 148 34 47 217 225 
224 160 32 24 160 165 42 48 234 237 
225 65 13 25 148 147 52 48 213 220 
226 160 32 39 150 124 25 38 207 201 
227 165 33 48 188 174 37 49 258 271 
228 120 24 21 115 111 28 34 167 166 
229 75 15 21 154 139 36 43 205 203 
230 40 8 5 125 133 50 44 183 182 
231 100 20 6 186 192 62 60 268 258 
232 115 23 10 108 117 44 38 175 165 
231 65 13 0 146 146 43 47 202 193 
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Sam- TG VLDL- VLD LDL- LDL- HDL- HDL- TC TC 
pie C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
234 120 24 16 173 160 29 48 226 224 
235 100 20 8 104 106 33 39 157 153 
236 115 23 28 159 146 31 40 213 214 
237 100 20 21 151 145 47 42 218 208 
238 412 82 55 145 150 29 35 256 240 
239 165 33 18 112 127 46 38 191 183 
240 70 14 22 173 182 86 49 273 253 
241 60 12 13 120 116 54 39 186 168 
242 100 20 12 140 139 43 49 203 200 
243 145 29 21 142 143 40 49 211 213 
244 40 8 8 91 101 52 39 151 148 
245 85 17 17 236 211 34 61 287 289 
246 50 10 8 148 151 63 49 221 208 
247 150 30 21 140 154 51 44 221 219 
248 140 28 19 197 181 35 52 260 252 
249 125 25 22 78 106 61 32 164 160 
250 55 11 1 146 135 40 46 197 182 
251 75 15 8 146 146 51 48 212 202 
252 110 22 14 163 163 42 51 227 228 
253 110 22 20 131 152 72 43 225 215 
254 80 16 7 143 140 39 49 198 196 
255 135 27 23 134 139 47 42 208 204 
256 110 22 22 157 172 66 51 245 245 
257 125 25 13 208 188 31 59 264 260 
258 49 10 10 114 43 167 167 
259 100 20 18 123 116 30 41 173 175 
260 160 32 14 179 168 27 50 238 232 
261 29 167 49 245 
262 70 14 11 127 122 48 50 189 183 
263 5 113 52 170 
264 11 164 64 239 
265 100 20 4 111 132 55 66 186 202 
266 470 94 44 204 208 36 51 334 303 
267 145 29 16 167 160 54 46 250 222 
268 45 9 13 145 131 58 52 212 196 
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Sam- TG VLDL- VLD LDL-C LDL- HDL- HDL- TC TC 
pie C L-C (a) C C C (a) (b) (a) (b) (b) (a) (b) 
269 260 52 43 181 154 26 47 259 244 
270 140 28 29 70 98 54 40 152 167 
271 155 31 23 145 131 29 43 205 197 
272 340 68 57 157 151 27 37 252 245 
273 75 15 0 207 197 33 65 255 262 
274 145 29 27 178 161 29 47 236 235 
275 270 54 53 140 136 31 32 225 221 
276 110 22 24 132 130 43 43 197 197 
277 165 33 25 149 149 31 42 213 216 
278 10 108 38 156 
279 2 143 48 193 
280 16 116 35 167 
281 7 202 56 265 
282 3 152 45 200 
283 0 142 44 186 
284 0 120 36 156 
285 275 55 33 142 148 32 30 229 211 
286 85 17 7 141 152 51 50 209 209 
287 4 160 56 220 
288 3 108 44 155 
289 8 129 42 179 
290 95 19 17 99 123 77 38 195 178 
291 215 43 19 137 154 35 41 215 214 
292 9 120 39 168 
293 6 112 41 159 
294 7 139 48 194 
295 125 25 11 155 139 30 42 210 192 
296 95 19 2 156 170 78 55 253 227 
297 17 128 55 200 
298 16 110 50 176 
299 160 32 1 153 150 26 48 211 199 
300 0 132 46 178 
301 101 94 5 200 
302 24 141 45 210 
303 7 141 45 193 
Sam- TG VLDL- VLD LDL-C LDL-
pie C L-C (a) C (a) (b) (b) 
304 145 29 37 102 115 
305 35 7 20 45 48 
306 110 22 7 169 176 
307 325 65 51 99 120 
308 85 17 4 148 180 
309 165 33 29 121 139 
310 110 22 7 88 120 
311 240 48 11 176 190 
312 100 20 4 205 199 
313 100 20 1 83 130 
314 110 22 14 150 143 
315 105 21 15 121 124 
316 60 12 3 116 128 
317 380 76 50 153 189 
318 60 12 14 40 42 
319 100 20 5 130 132 
320 150 30 29 108 113 
321 95 19 25 96 93 
322 140 28 22 120 129 
323 170 34 17 126 134 
324 130 26 18 114 124 
325 475 95 66 103 136 
326 160 32 4 172 186 
327 55 11 8 58 70 
328 75 15 31 78 91 
329 185 37 27 170 167 
(a) Lipid profile reported by the external laboratory. 
(b) Lipid profile obtained by the alternative method. 
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HDL- HDL- TC TC 
C C (a) (b) (a) (b) 
23 33 154 185 
37 22 89 90 
36 50 227 233 
26 22 190 193 
55 53 220 237 
42 41 196 209 
46 39 156 166 
37 59 261 260 
36 63 261 266 
70 47 173 178 
34 52 206 209 
40 42 182 181 
52 48 180 179 
49 40 278 279 
29 22 81 78 
34 48 184 185 
37 37 175 179 
52 33 167 151 
51 39 199 190 
43 31 203 182 
44 26 184 168 
30 12 228 214 
45 46 249 236 
35 28 104 106 
55 28 148 150 
38 49 245 243 
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II. Lipid profiles of samples from Roche Biomedical Laboratory. 
Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
1 842 69 116 29 208 214 
2 406 81 148 39 268 268 
3 511 99 104 14 227 219 
4 518 102 194 43 321 339 
5 416 85 69 16 169 170 
6 631 132 155 20 308 307 
7 709 137 188 26 300 351 
8 433 74 153 37 251 264 
9 544 109 107 14 235 230 
10 435 87 63 87 115 34 39 208 217 
11 1110 185 229 22 396 436 
12 537 121 139 23 271 283 
13 1305 202 119 -11 272 310 
14 443 89 83 115 134 42 31 246 248 
15 409 83 194 49 291 326 
16 459 86 71 18 163 175 
17 436 106 95 19 214 220 
18 632 113 137 27 272 277 
19 610 103 122 18 244 243 
20 411 82 73 147 161 33 37 262 271 
21 562 83 149 32 262 264 
22 419 84 79 123 140 38 38 245 257 
23 474 111 170 33 311 314 
24 411 82 95 183 180 53 41 318 316 
25 391 78 79 126 121 36 32 240 232 
26 398 80 80 177 171 42 41 299 292 
27 416 83 93 122 143 30 28 235 264 
28 429 86 78 89 126 30 22 205 226 
29 412 82 71 175 187 33 39 290 297 
30 420 84 80 51 77 29 15 164 172 
31 413 83 96 101 118 27 17 211 231 
32 459 92 131 196 200 36 14 324 345 
33 1239 226 57 -49 204 234 
14 895 151 100 -16 207 235 
Sam- TG VLD VLD LDL- LDL-
pie L-C L-C C C (a) (b) (a) (b) 
35 681 133 74 
36 3280 504 109 
37 515 79 184 
38 585 149 130 
39 537 107 111 129 163 
40 436 87 110 68 95 
41 440 88 94 60 120 
42 558 112 96 125 168 
43 432 86 67 138 193 
44 957 137 196 
45 681 104 147 
46 1413 266 88 
47 759 128 112 
48 481 96 89 176 188 
49 401 80 49 120 190 
50 466 93 74 178 203 
51 842 141 163 
52 692 151 157 
53 587 126 76 
(a) Lipid profile reported by the external laboratory. 
(b) Lipid profile obtained by the alternative method 
120 
HDL- HDL- TC TC 
C C (a) (b) (a) (b) 
-9 183 198 
-174 387 439 
32 281 295 
-4 260 275 
27 17 263 291 
25 3 180 208 
59 17 207 231 
28 27 265 291 
51 34 275 294 
3 291 336 
7 238 258 
-66 259 288 
-5 204 235 
20 22 292 299 
39 41 239 280 
25 35 296 312 
3 250 307 
10 281 318 
-6 168 196 
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III. Lipid profiles of samples from Stillwater Medical Center. 
Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
1 1110 168 37 -16 172 189 
2 910 102 112 9 198 223 
3 1450 257 12 -68 213 201 
4 420 62 131 27 217 220 
5 990 146 122 0 272 268 
6 1350 197 148 -15 330 
7 325 65 34 199 77 310 
8 330 66 51 149 54 254 
9 358 72 64 59 25 148 
10 388 78 66 138 44 248 
11 472 67 116 31 214 
12 306 61 55 117 150 40 44 218 249 
13 202 40 12 97 32 147 141 
14 253 51 16 214 73 308 303 
15 268 54 24 144 48 212 216 
16 1710 182 219 10 425 411 
17 297 59 21 209 57 300 287 
18 322 64 32 137 34 203 203 
19 327 65 40 105 25 184 170 
20 364 73 51 76 15 154 142 
21 366 73 86 98 13 219 197 
22 417 60 143 34 258 237 
23 641 63 178 34 298 275 
24 1542 208 186 -4 410 390 
25 666 58 201 48 325 307 
26 557 2 90 35 125 127 
27 543 74 164 28 260 266 
28 539 70 70 7 157 147 
29 436 71 126 28 229 225 
30 376 75 91 184 168 44 27 303 286 
31 630 62 98 20 189 180 
32 493 52 185 44 281 281 
33 420 48 151 39 236 238 
34 373 75 34 188 49 260 271 
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Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
35 273 55 17 186 55 252 258 
36 325 65 37 111 29 172 177 
37 337 67 46 152 36 212 234 
38 349 70 17 158 52 218 227 
39 355 71 41 165 41 250 247 
40 398 80 43 227 55 316 325 
41 400 33 173 45 248 251 
42 402 23 161 48 223 232 
43 405 44 131 36 209 211 
44 429 78 142 23 237 243 
45 443 67 239 51 339 357 
46 264 53 28 109 39 158 176 
47 278 56 56 179 41 260 276 
48 280 56 46 95 21 159 162 
49 284 57 50 138 29 213 217 
50 293 59 19 76 27 115 122 
51 306 61 37 112 31 185 180 
52 343 69 44 155 47 245 246 
53 316 63 46 188 50 281 284 
54 322 64 50 170 43 258 263 
55 590 67 193 45 297 305 
56 267 53 47 162 43 245 252 
57 332 66 60 130 37 209 227 
58 461 83 163 29 267 275 
59 476 81 131 25 259 237 
60 261 52 41 124 36 215 201 
61 295 59 48 96 27 174 171 
62 311 62 36 171 53 274 260 
63 315 63 57 133 35 229 225 
64 320 63 33 111 38 184 182 
65 325 65 13 74 33 119 120 
66 327 65 29 214 64 314 307 
67 358 72 51 112 32 191 195 
68 379 76 56 144 38 231 238 
69 382 76 54 206 57 320 317 
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Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) 
(a) (b) (a) (b) (a) (b) 
70 399 80 71 155 36 270 262 
71 420 61 116 29 211 206 
72 412 91 153 30 281 274 
73 443 68 173 38 284 279 
74 443 46 151 48 243 245 
75 451 48 133 36 225 217 
76 525 68 172 43 295 283 
77 577 78 160 35 271 273 
78 766 166 36 -28 182 174 
79 255 51 37 133 41 214 211 
80 254 51 27 112 36 184 175 
81 265 53 54 108 31 191 193 
82 1540 181 42 -36 188 187 
83 310 62 71 120 20 215 211 
84 286 57 56 158 48 252 262 
85 267 53 31 87 43 161 161 
86 280 56 37 88 25 156 150 
87 283 57 53 112 135 53 32 222 220 
88 299 60 49 174 48 278 271 
89 314 63 42 183 181 32 52 278 275 
90 332 66 37 172 49 273 258 
91 336 67 50 192 49 297 291 
92 341 68 61 142 34 246 237 
93 344 69 38 98 33 163 169 
94 345 69 39 157 42 244 238 
95 368 74 51 175 44 286 270 
96 294 59 7 75 35 115 117 
97 376 75 66 160 36 247 262 
98 302 60 49 126 37 215 212 
99 297 59 38 133 43 204 214 
100 404 51 168 47 260 266 
101 409 43 159 49 246 251 
102 640 89 50 12 158 151 
103 634 83 128 36 252 247 
104 552 95 110 21 243 226 
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Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) (a) (b) (a) (b) (a) (b) 
105 422 74 69 16 159 159 
106 430 81 145 39 282 265 
107 678 99 116 5 231 220 
108 374 75 67 98 19 187 185 
109 350 70 46 108 25 183 179 
110 1209 135 5 -23 122 117 
111 780 98 81 8 172 187 
112 617 102 59 -10 147 151 
113 485 87 103 14 197 204 
114 466 82 149 25 258 256 
115 460 68 47 12 125 127 
116 402 61 153 39 228 253 
117 283 57 69 190 46 286 305 
118 290 58 49 94 31 168 174 
119 259 52 39 96 32 154 167 
120 687 123 107 9 235 239 
121 600 87 96 15 189 198 
122 551 77 119 21 230 217 
123 511 85 120 7 211 212 
124 432 90 106 12 200 208 
125 389 78 63 67 10 136 140 
126 364 73 59 140 30 223 229 
127 346 69 70 225 45 321 340 
128 339 68 62 125 22 195 209 
129 329 66 58 215 50 289 323 
130 326 65 60 95 30 149 185 
131 304 61 54 117 29 176 200 
132 839 125 151 -4 264 272 
133 557 72 172 22 268 266 
134 484 42 163 30 243 235 
135 455 58 111 5 187 174 
136 406 43 215 29 306 287 
137 395 79 68 86 6 180 160 
138 370 74 58 177 26 268 261 
139 370 74 65 135 15 227 215 
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Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) 
(a) (b) (a) (b) (a) (b) 
140 368 74 63 217 42 336 322 
141 362 72 66 135 28 226 229 
142 357 71 56 210 53 292 319 
143 328 66 70 98 15 177 183 
144 327 65 51 111 25 179 187 
145 302 60 60 98 19 168 177 
146 276 55 30 99 28 146 157 
147 266 53 48 55 12 125 115 
148 253 51 62 312 56 439 430 
149 632 134 143 -8 254 269 
150 444 54 145 28 222 227 
151 272 54 33 23 6 58 62 
152 775 90 102 6 187 198 
153 636 110 184 15 291 309 
154 551 97 185 21 295 303 
155 431 95 172 22 266 289 
156 426 82 122 10 197 214 
157 387 77 82 168 19 248 269 
158 387 77 68 145 21 217 234 
159 368 74 67 206 34 278 307 
160 309 62 61 86 9 138 156 
161 624 80 164 25 265 269 
162 419 49 201 31 253 281 
163 413 71 212 35 308 318 
164 392 78 64 166 23 250 253 
165 388 78 61 103 16 171 180 
166 359 72 65 125 18 208 208 
167 383 77 67 214 43 319 324 
168 354 71 58 163 31 234 252 
169 190 75 -60 205 
170 648 79 135 8 236 222 
171 490 96 170 19 267 285 
172 429 58 79 8 153 145 
173 398 80 63 136 24 253 223 
174 365 73 61 164 30 279 255 
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Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) 
(a) (b) (a) (b) (a) (b) 
175 398 80 68 122 18 204 208 
176 338 68 62 84 13 160 159 
177 670 93 205 33 329 331 
178 610 115 194 20 307 329 
179 604 112 110 0 220 222 
180 539 87 138 18 241 243 
181 496 39 68 11 120 118 
182 458 88 38 -13 114 113 
183 391 78 76 159 23 250 258 
184 363 73 66 142 27 225 235 
185 318 64 71 224 44 333 339 
186 338 68 79 184 34 287 297 
187 278 56 75 188 37 295 300 
188 360 72 67 146 24 222 237 
189 355 71 86 167 26 250 279 
190 329 66 49 179 43 237 271 
191 297 59 75 222 41 310 338 
192 309 62 62 207 44 282 313 
193 322 64 50 113 29 161 192 
194 436 77 160 29 244 266 
195 407 62 150 28 222 240 
196 510 84 248 43 344 375 
197 350 70 63 120 22 183 205 
198 353 71 46 151 34 221 231 
199 521 86 89 10 171 185 
200 279 56 41 102 25 166 168 
201 327 65 32 114 32 170 178 
202 404 30 114 34 180 178 
203 527 76 202 37 300 315 
204 532 65 116 21 189 202 
205 758 135 107 -4 219 238 
206 610 82 164 39 241 285 
207 585 78 174 33 268 285 
208 570 72 128 22 212 222 
209 556 55 166 37 240 258 
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Sam- TG VLD VLD LDL- LDL- HDL- HDL- TC TC 
pie L-C L-C C C C C (a) (b) 
(a) (b) (a) (b) (a) (b) 
210 492 43 209 54 290 306 
211 492 87 144 21 240 252 
212 455 72 115 22 217 209 
213 394 79 62 169 32 242 263 
214 366 73 -8 211 69 238 272 
215 258 52 41 235 55 310 331 
216 269 54 53 107 22 171 182 
217 271 54 35 111 39 160 185 
218 537 57 54 9 119 120 
219 421 43 73 25 114 141 
220 917 122 18 -15 120 125 
221 375 75 49 85 21 150 155 
222 318 64 40 240 63 310 343 
223 337 67 45 96 33 159 174 
224 845 172 151 -1 314 322 
225 702 88 39 -4 118 123 
226 575 84 211 33 318 328 
227 467 38 102 26 159 166 
228 401 84 120 22 200 226 
229 389 78 49 215 54 287 318 
230 368 74 71 125 23 208 219 
231 349 70 27 186 51 260 264 
232 295 59 72 214 46 314 332 
233 291 58 46 112 33 173 191 
234 742 112 21 -11 127 122 
235 674 94 242 32 353 368 
236 484 67 117 22 197 206 
237 398 80 58 217 51 312 326 
238 380 76 42 172 44 250 258 
239 342 68 32 210 57 289 299 
240 262 52 35 105 33 159 173 
241 250 50 25 72 23 126 120 
242 375 75 31 82 24 137 137 
243 413 55 81 19 147 155 
244 769 185 189 -10 370 364 
Sam- TG VLD VLD LDL- LDL-
pie L-C L-C C C (a) (b) (a) (b) 
245 449 68 104 
246 440 38 236 
247 415 46 205 
248 364 73 35 197 
249 329 64 11 253 
250 302 60 19 282 
251 250 50 33 74 
(a) Lipid profile reported by the external laboratory. 
(b) Lipid profile obtained by the alternative method. 
HDL- HDL-
C C (a) (b) 
24 
59 
51 
55 
78 
77 
30 
IV. Lipid profiles of samples from University of Cape Town. 
Sam- TG VLD VLD LDL- LDL-
pie L-C L-C C C (a) (b) (a) (b) 
1 142 33 14 94 111 
2 212 71 14 84 151 
3 389 105 40 116 161 
4 912 145 162 153 160 
5 204 24 12 112 127 
6 460 159 65 150 205 
7 186 49 21 74 97 
8 80 12 13 101 136 
9 230 7 16 233 233 
10 88 8 17 189 168 
(a) Lipid profile reported by the external laboratory. 
(b) Lipid profile obtained by the alternative method 
HDL- HDL-
C C 
(a) (b) 
35 43 
58 53 
23 46 
31 1 
50 46 
27 49 
35 40 
77 54 
46 74 
39 58 
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TC TC 
(a) (b) 
190 196 
324 333 
294 302 
277 287 
326 342 
361 378 
133 137 
TC TC (a) (b) 
162 168 
213 218 
244 247 
329 323 
186 185 
336 319 
158 158 
190 203 
286 323 
236 243 
Appendix C 
Lipid Profiles Obtained for the Precision Studies 
AS 1 1 . amne 
VLDL-C LDL-C HDL-C TC 
mg/dL mg/dL mg/dL mg/dL 
(a) Enzvmatic 32 160 42 234 
(b) Soectroscooic 
1 25 170 48 243 
2 28 167 43 238 
3 28 165 45 238 
4 22 169 49 240 
5 26 163 47 236 
6 30 157 46 233 
7 23 169 48 240 
8 25 161 47 233 
9 24 164 49 237 
10 23 167 48 238 
mean 25 165 47 238 
S.D. 2.6 4.1 1.9 3.1 
%C.V. 10.2 2.5 4.0 1.3 
B S 1 2 . amoe 
VLDL-C LDL-C HDL-C TC 
mg/dL mg/dL mg/dL mg/dL 
(a) Enzvmatic 7 45 37 89 
(b) Soectroscooic 
1 19 49 24 92 
2 18 50 25 93 
3 14 53 25 92 
4 18 51 24 93 
5 23 45 21 89 
6 23 45 21 89 I mean 19 49 23 91 
129 
130 
C S I 3 . amne 
VLDL-C LDL-C HDL-C TC 
mg/dL mg/dL mg/dL mg/dL 
(a) Enzvmatic 20 104 33 157 
(b) Snectrosconic 
1 5 112 41 158 
2 8 105 39 152 
3 8 106 41 155 
4 6 110 41 157 
5 1 112 42 155 
6 17 101 37 155 
7 4 108 40 152 
8 12 102 41 155 
9 6 105 41 152 
10 10 112 40 162 
mean 8 107 40 155 
S.D. 4.5 4.1 1.4 3.1 
%C.V. 58.4 3.8 3.5 2.0 
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